Podcasts about glaxosmithkline gsk

Recent allegations exposed by the Wall Street Journal and New York Post, suggest that senior Pfizer executives may have intentionally delayed the release of their COVID-19 vaccine trial results to influence the outcome of the 2020 U.S. presidential election. Former Pfizer scientist Dr. Philip Dormitzer reportedly told colleagues at GlaxoSmithKline (GSK) that the timing of the vaccine's announcement was "not a coincidence," implying a deliberate effort to withhold positive trial data until after Election Day. These claims have prompted a Republican-led House Judiciary Committee investigation, seeking documents from Pfizer and testimony from Dr. Dormitzer. The episode explores the potential motivations behind such a delay, including concerns about political repercussions from a second Trump administration. Plus, Joe Biden has advanced, terminal prostate cancer. Dr. Harvey Risch is our guest to explain why there is no way this can be a new diagnosis. The Wellness Company prides itself on pushing back against censorship and tyranny. It's why it has developed a series of prescription drug medical emergency kits including a parasite cleanse that prescribed directly to you and delivered to your door to use incase of an emergency. BACK IN STOCK after 3x Sell-Outs! The Gold Standard in quality: the only product of its kind compounded by a 50-state licensed US pharmacy. Use promo code: GRANT to save 10% at: (Click Link Below) https://www.twc.health/products/ivermectin-mebendazole?ref=GRANT Also the prescription medical kits will allow you will have on hand much needed antibiotics. See omnystudio.com/listener for privacy information.

Voor het 24e jaar op rij onderzocht Randstad de aantrekkelijkheid van de grootste werkgevers in ons land bij 12.000 respondenten. Voor het tweede jaar op rij is GlaxoSmithKline (GSK) de meest aantrekkelijke werkgever. Bij de lokale besturen, die dit jaar als aparte categorie werden onderzocht, is de stad Namen de meest aantrekkelijke werkgever. Ondanks de krappe arbeidsmarkt zijn Belgische werknemers niet veeleisender ten opzichte van hun (potentiële) werkgever. In een 4-delige podcastreeks zoom ik in op de belangrijkste resultaten van de Randstad Employer Brand Studie en ga ik in gesprek met de winnaars. Ik ben daarvoor te gast bij Randstad in hun hoofdkantoor in Brussel. In de vierde aflevering kruip ik in het hoofd van Gretel Vlogaert, National Manager Career Development Randstad RiseSmart. We gaan het hebben over het belang van leiderschap in employer branding en samen met Gretel zetten we jou op weg om de resultaten van de Randstad Employer Brand studie om te zetten in de dagelijkse praktijk. Veel kijk- en luisterplezier!+++Honger naar meer? SCHRIJF JE IN VOOR DE NIEUWSBRIEF LEES DE ARTIKELS ABONNEER JE OP HET TIJDSCHRIFT And don't forget: it's a great time to be in HR!+++Opgenomen bij HQ Randstad België in Brussel

C'est la 24ème année consécutive que le prestataire de services en ressources humaines Randstad menait une enquête auprès de 12.000 répondants afin d'étudier l'attractivité des plus grands employeurs de Belgique. GlaxoSmithKline (GSK) se révèle l'employeur le plus attractif pour la deuxième année d'affilée. Déjà cinq fois vainqueur auparavant, GSK devient, avec six victoires, le détenteur du record absolu. Du côté des administrations locales, étudiées en tant que catégorie distincte cette année, c'est la ville de Namur qui décroche le titre d'employeur le plus attractif, devant Bruxelles et Gand. Dans une série de podcasts en quatre parties, je m'entretiens avec les gagnants et j'analyse les principaux résultats de l'étude Randstad sur la marque employeur. Pour ce faire, je suis l'invité de Randstad à son siège de Bruxelles. Pour cette épisode-ci, j'ai  invité Isabelle Leclercq, HR Country Head Belgium chez GSK et Laurence Leprince, directrice générale chez la ville de Namur.+++Honger naar meer? SCHRIJF JE IN VOOR DE NIEUWSBRIEF LEES DE ARTIKELS ABONNEER JE OP HET TIJDSCHRIFT It's a great time to be in HR!

oor het 24e jaar op rij onderzocht Randstad de aantrekkelijkheid van de grootste werkgevers in ons land bij 12.000 respondenten. Voor het tweede jaar op rij is GlaxoSmithKline (GSK) de meest aantrekkelijke werkgever. Bij de lokale besturen, die dit jaar als aparte categorie werden onderzocht, is de stad Namen de meest aantrekkelijke werkgever. Ondanks de krappe arbeidsmarkt zijn Belgische werknemers niet veeleisender ten opzichte van hun (potentiële) werkgever. In een 4-delige podcastreeks zoom ik in op de belangrijkste resultaten van de Randstad Employer Brand Studie en ga ik in gesprek met de winnaars. Ik ben daarvoor te gast bij Randstad in hun hoofdkantoor in Brussel. In deze aflevering kruip ik in het hoofd van Wim Van der Linden, woordvoerder bij Randstad en dat van Ann Vermeersch, Lead Advisor Talent Advisory bij Randstad. Veel kijk- en luisterplezier! +++Honger naar meer? SCHRIJF JE IN VOOR DE NIEUWSBRIEF LEES DE ARTIKELS ABONNEER JE OP HET TIJDSCHRIFT And don't forget: it's a great time to be in HR!+++Opgenomen bij HQ Randstad België in Brussel

C'est la 24ème année consécutive que le prestataire de services en ressources humaines Randstad menait une enquête auprès de 12.000 répondants afin d'étudier l'attractivité des plus grands employeurs de Belgique. GlaxoSmithKline (GSK) se révèle l'employeur le plus attractif pour la deuxième année d'affilée. Du côté des administrations locales, étudiées en tant que catégorie distincte cette année, c'est la ville de Namur qui décroche le titre d'employeur le plus attractif. Dans une série de podcasts en quatre parties, je m'entretiens avec les gagnants et j'analyse les principaux résultats de l'étude Randstad sur la marque employeur. Pour ce faire, je suis l'invité de Randstad à son siège de Bruxelles. Pour cette épisode-ci, j'ai rendez-vous avec Sébastien Cosentino, Senior Manager public sector chez Randstad et avec Olivier Lefevre, Director Operations Talent Advisory chez Randstad. +++Honger naar meer? SCHRIJF JE IN VOOR DE NIEUWSBRIEF LEES DE ARTIKELS ABONNEER JE OP HET TIJDSCHRIFT It's a great time to be in HR!

Samsung Biologics' James Choi discusses the CDMO's role in teaming up with Big Pharma to tackle sustainability in the biotech space.    This episode of the Voices of Biotech – brought to you by the BioProcess Insider Expression Platform – brings you an interesting conversation with Choi about the commitment to a “greener” supply chain.   In July 2023, CEOs from Roche, GlaxoSmithKline (GSK), AstraZeneca, Novo Nordisk, Merck KGaA, Sanofi, and contract development manufacturing organization Samsung Biologics signed an open letter calling on suppliers to commit to climate and sustainability targets.   The healthcare industry contributes approximately 5% of global greenhouse gas emissions, 50% of which comes from supply chains. The letter said called on biopharma collaborators to speedily move towards a “greener, more efficient, and circular” process. Additionally, it urged suppliers to sign-up to a joint minimum climate and sustainability targets, based around fundamental commitments laid out by the same seven firms ahead of COP27 in November 2022.   Choi, executive vice president, chief marketing officer, and head of sales support and global public affairs at Samsung Biologics, speaks about the CDMO's involvement in teaming up with Big Pharma players to reach specific sustainability goals by 2025 and beyond. He talks about the important role a service provider plays in being more sustainable, Samsung Biologics' own sustainability measures at the firm, and how the coalition came to fruition.   On top of being part of a coalition to advance sustainability in the sector, Choi also talks in depth about the buildout of its facilities and the measures they have put in place to ensure the next plant is “greener than the one before.”   The latest episode can be found below or through the BioProcess Insider Expression Platform at, Spotify, Apple iTunes, Google podcasts, or wherever you get your podcasts.  

A former RAF pilot and combat base commander is helping to provide a new generation of supply chain professionals for some of the world's biggest companies. Richard Atkinson said his military background was very “relevant” to his current role as deputy director of the Supply Chain Leadership programme at Aston University. The former air commodore, who once flew Tornado and Phantom fighter jets and was station commander of RAF Leuchars in Scotland, appears in the latest episode of the Aston means business podcast series, presented by journalist Steve Dyson. Mr Atkinson, now a teaching fellow at Aston University, said that he was enjoying passing on his knowledge of how to tackle modern day logistics issues to ‘learner colleagues', along with the experience of many other experts. He said: “When I was director of Air Operations in Afghanistan, where we were supporting the development of Afghanistan, the people I spoke to the most were our logisticians, understanding the novel supply chains required. “And even today, with troubles in the Horn of Africa, the Middle East and with the illegal invasion of Ukraine by Russia, all of these conflicts depend upon supply chains, but they all impact supply chains as well. “That's why our programme is so relevant to create the future generation of supply chain leaders.” Mr Atkinson explained that NATO's role in Afghanistan meant military forces had to be adaptable every day in terms of supply chains. He said the big challenge was global warming which would “strategically impact migration and supply chains across the world”. “In future, we need to hit situations where we can deliver water, food and medicine where they are needed, at the right time, safely, securely and sustainably. So, we need our political leaders, our generals, our admirals, our air marshals, but also supply chain professionals to come up with these solutions, these alternative routes.” Mr Atkinson said Aston University was the UK's leading faculty in supply chains with its BSc degree apprenticeship in Supply Chain Management. The programme started four years ago with four companies and now has 30 to 40 companies and hundreds of ‘learner colleagues'. Companies using the programme include pharmaceutical giant GSK, Coca-Cola, Jaguar Land Rover, DHL, and many other companies. Mr Atkinson highlighted how GlaxoSmithKline (GSK) had “wonderful scientists and chemists” to create life-changing drugs, such as the new Shingles vaccine, but that they equally needed “amazing logisticians to make sure they get to the right people in the right place at the right time”. Tim Buchanan, apprenticeship levy lead for GSK, was also interviewed as part of the podcast. He explained how GSK is based in 133 countries around the world, which means global issues impacted in terms of bringing raw materials in, processing them into the drugs that appear on shelves, and then moving them back out to markets. Mr Buchanan praised the programme at Aston University and said: “Getting the new generation of supply chain apprentices up to speed, having them gain the experience … is crucial to the way we go forward. “We continually know we've got to have a group of new people coming in with the skills that Aston University is providing.” The first few apprentices, who are already full-time employees, will complete the programme this year. Mr Buchanan said the three main reasons for going on the programme were academics from Aston University going on site to meet GSK line managers, the course having “matured” after listening to feedback and “very high enthusiasm” from the apprentices about the learning. He added: “We wouldn't be returning if we didn't think there was value in the programme.” Mr Atkinson agreed, pointing out that Aston University was “filling a gap in the market”, which was crucial with the UK having “teetered into a recession” and businesses struggling. He said: “Let us bring our talent to you to help develop your talent for the future solutions.”

This episode features an interview with Yang Liu, PhD, founder, chairman, CEO and chief scientific officer; and Abid Ansari, MBA, chief financial officer at OncoC4, a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. This includes first-in-class immunotherapy products such as novel antibodies and CAR T-cell treatments targeting CTLA-4.OncoC4 is a spinout of OncoImmune, which was acquired by Merck in December 2020. OncoImmune was founded in 2000 based on the scientific discoveries of the company's founders who moved their lead product from a basic concept into clinical trials for multiple indications.Dr. Liu is recognized internationally for his research on immune recognition of cancer and activation of lymphocytes. He has received several academic and research awards including the Snyder Award for Cancer Research in 2015, and was elected to the rank of fellow at the American Association for Advancement of Science (AAAS) in 2004 for his pioneering contribution to innate immunity, T cell costimulation and cancer immunology. Prior to serving full-time as OncoC4's CEO, Dr. Liu was a faculty member at multiple academic institutions, including New York University and the Ohio State University.Abid Ansari is a finance executive with a more 20-year track record in the life sciences industry encompassing corporate finance, fundraising, business development and investor relations experiences for public and private life science companies. Previously, he served as CFO of Artios, a UK-based DNA damage response company where he led the company's $153 million Series C fundraising. Earlier in his career, Abid held positions at GlaxoSmithKline (GSK) in deal finance and portfolio management. Tune into the episode to hear more about the development of new, cutting-edge cancer treatments, including current challenges in oncology and immunotherapies. Also hear about OncoC4's collaborations including a co-development commercialization partnership with BioNTech on its lead product and a collaboration with Merck. For more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Cameroon has begun the world's first major malaria vaccine program for children.喀麦隆已启动世界上第一个针对儿童的大型疟疾疫苗计划。The campaign launched Monday in the Central African nation. Health officials called the effort a major step in the fight against the disease across Africa. The continent accounts for about 95 percent of the world's malaria deaths.该活动周一在这个中非国家发起。 卫生官员称这一努力是整个非洲抗击这种疾病的重要一步。 非洲大陆约占世界疟疾死亡人数的 95%。The World Health Organization (WHO) estimates the disease, which is spread through mosquitos, kills more than 600,000 people a year. Most of the deaths involve young children.世界卫生组织 (WHO) 估计，这种通过蚊子传播的疾病每年导致超过 60 万人死亡。 大多数死亡涉及幼儿。The vaccine, called RTS.S, was developed by British drug company GlaxoSmithKline (GSK). It is meant to work with other preventive measures, such as the use of bed nets, to fight the disease.该疫苗名为RTS.S，由英国制药公司葛兰素史克（GSK）开发。 它旨在与其他预防措施（例如使用蚊帐）一起对抗这种疾病。Cameroon is the first country to offer vaccine injections through a routine program after successful tests, or trials, were carried out in Ghana and Kenya. Cameroon hopes to vaccinate about 250,000 children this year and next.在加纳和肯尼亚进行成功的测试或试验后，喀麦隆成为第一个通过常规计划提供疫苗注射的国家。 喀麦隆希望今明两年为约25万名儿童接种疫苗。The international vaccine alliance called Gavi has said 19 other countries aim to launch their own campaigns this year. About 6.6 million children in those countries are to receive malaria vaccinations in 2024 and 2025.名为 Gavi 的国际疫苗联盟表示，其他 19 个国家计划在今年发起自己的疫苗接种运动。 2024 年和 2025 年，这些国家约有 660 万儿童将接受疟疾疫苗接种。"For a long time, we have been waiting for a day like this," said Mohammed Abdulaziz. He is with the African Centers for Disease Control and Prevention. Abdulaziz spoke during a joint news briefing with the WHO, Gavi and other organizations.穆罕默德·阿卜杜勒阿齐兹说：“很长一段时间以来，我们一直在等待这样的一天。” 他在非洲疾病控制和预防中心工作。 阿卜杜勒阿齐兹在与世界卫生组织、全球免疫联盟和其他组织举行的联合新闻发布会上发表了讲话。Cameroon is using one of two recently approved malaria vaccines, called Mosquirix. When the WHO approved the vaccine two years ago, officials admitted it was not perfect. But they noted its use could sharply reduce severe infections and hospitalizations.喀麦隆正在使用最近批准的两种疟疾疫苗之一，称为 Mosquirix。 当世界卫生组织两年前批准该疫苗时，官员们承认它并不完美。 但他们指出，它的使用可以大幅减少严重感染和住院治疗。The GSK-produced shot is only about 30 percent effective. It requires four shots, or doses. Tests have shown the vaccine's protection begins to weaken after several months. GSK has said it can only produce about 15 million doses of Mosquirix a year.葛兰素史克生产的注射剂只有约 30% 的效率。 它需要四次注射或剂量。 测试表明疫苗的保护作用在几个月后开始减弱。 GSK 表示，每年只能生产约 1500 万剂 Mosquirix。Some experts believe a second malaria vaccine developed by Oxford University and approved by the WHO in October may be a better solution. That vaccine, called R21, is less costly and only requires three doses.一些专家认为，由牛津大学开发并于 10 月获得世界卫生组织批准的第二种疟疾疫苗可能是更好的解决方案。 这种疫苗称为 R21，成本较低，并且只需要三剂。

The Finance Ministry is looking to raise USD500 million in a bond issuance in India in 2024, Minister said. The bond would be denominated in INR. The tax revenue on the Suez Canal Authority's income during 1Q23/24 increased by 151.6% to EGP21.4 billion.The CBE is currently negotiating with the UAE to roll over a USD3 billion deposit, due current December.The African Finance Corporation aims to pump investments worth more than USD1 billion into mega projects in the Egyptian market during the coming period.From COP28: Six major oil players, including BP, Eni, and Total Energies, each pledged USD25 million for a new fund that will help oil companies across developing countries bring down their methane emissions. We published our 3Q23 Cement Wrap Up and Valuation Updates report today, where:•We upgraded our FV for ARCC to EGP13.01/share up from EGP9.94/share and maintain our Overweight recommendation for the stock.•We upgraded our FV for MCQE to EGP22.36/share up from EGP15.18/share and maintain our Equalweight recommendation for the stock.•We upgraded our FV for MBSC to EGP44.17/share up from EGP25.73/share and maintain our Equalweight recommendation for the stock.SWDY (FV: EGP34.96, OW) signed a MoU with Indonesian state electricity distributor PT PLN (Persero) to help the Indonesian government link its new renewable energy generators with the national electricity grid.SWDY's subsidiary, Elsewedy Industrial Development, and Futurefert inked the land allocation agreement to set up a USD50 million fertilizer complex in Elsewedy's Sokhna 360 industrial zone.Also, Elsewedy Industrial Development awarded the Chinese fiberglass manufacturer Jushi a 60k-sqm plot in its Industrial Sokhna project located in the TEDA zone to expand its factory in China's TEDA trade zone with investments of USD8 million.We upgraded our FV for MFPC to EGP387/share. Our FV takes into account the following:•Updated macro assumptions (FX rates, interest rates, and inflation).•Global Urea prices outlook.•Those yielded a FV/share of EGP261.50/share.•We also included some of the company's future plans like the revamp and melamine project.MFPC is currently trading at 2024f P/E of 15.2x and EV/EBITDA of 10.4x.A consortium, which includes Helwan Fertilizers, ABUK, and Al Ahly Capital Holding, now have their eyes on a green ammonia project. The proposed project would require USD1.2 billion of investment, 70% of which would be financed by bank loans and the remainder from the companies' cash reserves.The Sovereign Fund of Egypt will announce new partnerships on the green ammonia front during COP28, be it through already existing green plants or greening existing ammonia plants, CEO Ayman Soliman said.PHDC (FV: EGP5.59, OW) signed an agreement with Marriott International to develop a new hotel, the Ritz-Carlton Palm Hills, in PHDC's Palmet project in West Cairo. The hotel's investment cost is estimated at EGP4.0 billion.MHOT declared 1:1 stock dividends. Record date is 20 Dec 2023. Distribution date is 21 Dec 2023.BTFH has applied to the FRA for initial approval to set up an SME-focused lender. The firm would be set up with a EGP250 million in capital. The International Finance Corporation (IFC) has agreed to lend USD50 million in sharia-compliant financing to SAUD to finance MSMEs. ValU will provide financing plans allowing people to purchase vaccines from GlaxoSmithKline (GSK) under an agreement signed by the two firms.The Supply Ministry has poured 50k tons of sugar into the local market to be sold at EGP27/kg in an effort to stabilize the marketAccording to local media, GB Capital's subsidiaries will be issuing securtitization bonds of EGP8.5 billion by the end of 2023.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Advocate Health experienced slower growth in the third quarter of 2023, although it remained profitable for the first nine months of the year. A review of the 340B drug discount program found mixed evidence on how hospitals use the funds. Some studies suggest that hospitals use the savings for purposes unrelated to patient care. Welltok, a patient engagement company, experienced a data breach in the spring that exposed the data of nearly 8.5 million people. Healthcare bankruptcies have increased in 2023 due to the expiration of federal COVID-19 funding, higher interest rates, regulatory changes, and labor shortages. The average per-worker cost of health benefits rose by 5.2% in 2023, with inflation and rising prescription drug costs being contributing factors. Hospitals are losing millions of dollars due to staff nurse turnover.Now let's move on to some exciting developments in the pharmaceutical industry. Regeneron and Sanofi are planning to seek new approval for their blockbuster drug, Dupixent, in the US after successful results from a phase 3 trial testing the drug in chronic obstructive pulmonary disease (COPD). The trial showed that Dupixent could reduce attacks and improve lung function in patients with the respiratory condition. Meanwhile, GSK's cancer drug Blenrep has received a surprise trial win. The drug was withdrawn from the US market last year due to negative data, but new study results may open the door to a relaunch. Xenon's depression drug, Xen1101, missed the main goal of a mid-stage trial. However, the company believes there were enough positive findings to warrant further study of the drug in depression. Novo Nordisk is planning to expand its French plant in a push to increase production of GLP-1 drugs. These developments come as dozens of cell and gene therapies are expected to receive FDA approval in 2024, leading to a need for enhanced patient access and cost management strategies.In other news, GlaxoSmithKline (GSK) is looking to bring back its antibody-drug conjugate Blenrep for the treatment of relapsed/refractory multiple myeloma. A year after withdrawing the drug from the US market, GSK has presented promising Phase III data that supports its potential comeback. The results showed that Blenrep, when used in combination with other therapies, significantly improved progression-free survival compared to standard of care alone. GSK plans to submit the data to regulatory authorities for review. Novo Nordisk is warning the EU of potential shortages of its GLP-1 drugs and is expanding production at its French site to meet the high demand for its drug Ozempic. 89bio has unveiled bullish long-term data for its nonalcoholic steatohepatitis (NASH) candidate pegozafermin. The drug showed statistically significant improvements in treating patients with NASH, positioning it as a potential treatment option for the condition. Overall, these developments highlight GSK's potential comeback with Blenrep, Dupixent's efficacy in COPD, Novo Nordisk's efforts to meet high demand for Ozempic, and 89bio's progress in developing a treatment for NASH.That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more updates in the world of Pharma and Biotech.

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Today we have some exciting news to share with you.## Bristol Myers Squibb Acquires Mirati TherapeuticsBristol Myers Squibb has announced its plans to acquire Mirati Therapeutics, a developer of drugs for Kras-mutant cancers, for $4.8 billion. This acquisition is part of Bristol Myers' strategy to expand its oncology portfolio and strengthen its position in the field of precision medicine. The deal also includes an additional $1 billion payment if an experimental cancer drug being developed by Mirati gains approval from US regulators.## GlaxoSmithKline Partners with Chongqing Zhifei Biological ProductsIn another deal, GlaxoSmithKline (GSK) has partnered with Chinese pharma company Chongqing Zhifei Biological Products to expand sales of its shingles vaccine, Shingrix, in China. GSK aims to double the sales of Shingrix by 2026. This partnership will help GSK tap into the growing demand for vaccines in China and strengthen its presence in the country's healthcare market.## FDA Rejects Alnylam's Application for Expanded ApprovalThe US Food and Drug Administration (FDA) has rejected Alnylam's application for expanded approval of its RNA drug Patisiran for the treatment of a rare heart condition. This setback delays Alnylam's plans to expand the use of Patisiran and highlights the challenges faced by biotech companies in gaining regulatory approval for new drugs.## Resurgence in Mergers and Acquisitions ActivityThe biotech industry is seeing a resurgence in mergers and acquisitions (M&A) activity, with nearly $7 billion in deals announced in the first nine days of October. This increase in M&A activity follows a relatively quiet third quarter and indicates a renewed interest in consolidation and strategic partnerships within the industry. Several FDA decisions to watch out for in the fourth quarter, including verdicts on drugs from Vertex, Bristol Myers, Amgen, Pfizer, and Alnylam, could impact the future growth and profitability of these companies.## HLTH Conference AnnouncementsMoving on to the HLTH conference in Las Vegas, there were several notable announcements. Venture capital firm General Catalyst is planning to buy a health system as part of its new health business, called the Health Assurance Transformation Corporation. Amazon Clinic is considering partnering with physical providers for care referrals, recognizing that some aspects of care are better done in person. Uber has partnered with Optum to add benefits cards to its health platform, making Uber a "patient entry point" into the health benefits system.## Updates in the Health IndustryThe recent three-day strike at Kaiser Permanente has ended, but unions and the health system have not reached an agreement on a new contract for over 75,000 workers. Best Buy is venturing into prescription-based medical device sales by selling continuous glucose monitoring systems. The Drug Enforcement Administration and the Department of Health and Human Services have extended telehealth prescribing rules for controlled substances virtually through the end of 2024. There was also a strike by healthcare workers at St. Francis Medical Center in Los Angeles and the introduction of a buy now, pay later card for medical expenses by PayZen.## Tune Therapeutics' Epigenetic Editing TherapiesTune Therapeutics, a biotech company, is developing epigenetic editing therapies as a potentially safer alternative to CRISPR-style gene therapies. While CRISPR-based treatments hold promise for curing chronic conditions, they also come with safety risks due to potential off-target effects. Tune Therapeutics aims to overcome these risks by "tuning" genes up or down using epigenetic editing. This approach could provide a safer and more precise method of gene editing.## FDA Advisory Committee to Discuss Sickle Cell Disease ApplicationThe FDA adviso

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Bill Gates' 400 million dollar bet - First Tuberculosis Vaccine in 100 years?, published by NickLaing on July 2, 2023 on The Effective Altruism Forum. Last week a young man Onekalit turned up with a nasty cough to a health center we operate in a youth prison in Gulu, Northern Uganda. The dry cough wore him down for over a month, but last week he finally managed to cough a bit of sputum into a small plastic container. The incredible Gates Foundation funded GeneXpert test confimed our fears – Tuberculosis But Onekalit will be OK – after 6-9 months of gruelling treatment, the TB will be cured. He will not become one of the 1.5 million people that TB kills every year, more than double that of malaria. After covid subsided TB has now regained the dubious honour of the world's deadliest infectious disease. The Gates Foundation helped bring the amazing GeneXpert diagnostic test to places like rural Uganda, but Bill and co. are now going a step further making their biggest ever 400 million dollar bet on a vaccine that initial trials show may be 50% effective in stopping TB progress from latent infection to deadly lung disease. The first new effective TB vaccine in over 100 years.Surprisingly this vaccine has been sitting around (in a form) doing nothing much for around 20 years. GlaxoSmithKline (GSK) bought the patent almost 20 years ago, before publishing a trial which showed it was actually quite good and could save millions of lives, then decided they couldn't make money from the vaccine so shelved it... Crazy stuff. Unfortunately, our economic system is not set up to bring a vaccine which could save hundreds of millions of future lives to market. Fortunately our economic system does allow people like Effective Altruists and Bill Gates to donate their own stacks of cash towards life saving endeavours that the market has failed to bring to fruition. This mind bogglingly expensive 550million dollar trail is necessary because TB is a slow disease. Slow to divide, slow to spread, slow to treat. Tracking and follow up TB takes far longer than for your average infectious disease. For malaria, within a year we can start to see whether a vaccine works. For TB it will take at least 5 times as long – 5 years or more before we know whether we are onto a winner. If the vaccine really is 50% effective, it could save around 10 million lives in the next 25 years, not to mention helping prevent the terrifying Antimicrobial Resistance (AMR) that TB has already partly achieved. 500 million died from Smallpox (“but not a single one more”) – over 1 billion have died from TB. We remain far a from “not a single one more” in the case of TB – but this could be a spectacular step in the right direction. Not his real name Although from an effective altruism perspective the suffering caused by malaria is worse, because malaria kills mostly young children, whereas TB kills people of all ages. I'm not sure about this, please correct me if I'm wrong Thanks for listening. To help us out with The Nonlinear Library or to learn more, please visit nonlinear.org

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Why GiveWell funded the rollout of the malaria vaccine, published by GiveWell on May 12, 2023 on The Effective Altruism Forum. Author: Audrey Cooper, GiveWell Philanthropy Advisor Since our founding in 2007, GiveWell has directed over $600 million to programs that aim to prevent malaria, a mosquito-borne disease that causes severe illness and death. Malaria is preventable and curable, yet it killed over 600,000 people in 2021—mostly young children in Africa.[1] Following the World Health Organization's approval of the RTS,S/AS01 malaria vaccine (RTS,S) in late 2021,[2] GiveWell directed $5 million to PATH to accelerate the rollout of the vaccine in certain areas of Ghana, Kenya, and Malawi. This grant aimed to enable these communities to gain access to the vaccine about a year earlier than they otherwise would, protecting hundreds of thousands of children from malaria.[3] Although we're very excited about the potential of the RTS,S malaria vaccine to save lives, it isn't a panacea. We still plan to support a range of malaria control interventions, including vaccines, nets, and antimalarial medicine. In this post, we will: Explain how we found the opportunity to fund the malaria vaccine Discuss why we funded this grant Share our plan for malaria funding moving forward Identifying a gap in vaccine access In October 2021, we shared our initial thoughts on the approval of the RTS,S malaria vaccine by the World Health Organization (WHO). At that point, we weren't sure whether the vaccine would be cost-effective and were not aware of any opportunities for private donors to support the expansion of vaccine access. In the following months, our conversations with PATH, a large global health nonprofit that we've previously funded, revealed that there might be an opportunity to help deploy the vaccine more quickly in certain regions. PATH had been supporting the delivery of the vaccine in Ghana, Kenya, and Malawi as part of the WHO-led pilot—the Malaria Vaccine Implementation Program (MVIP)—since the pilot began in 2019.[4] In order to generate evidence about the effectiveness of the vaccine, randomly selected areas in each country received the vaccine during the early years of the pilot, while “comparison areas” would receive the vaccine at a later date, if the vaccine was recommended by the WHO.[5] Once the vaccine had received approval from the WHO, the WHO and PATH believed there was an opportunity to build on the momentum and groundwork of the pilot to roll out the vaccine to the comparison areas as soon as possible. However, the expectation at the time was that expanding use to the comparison areas would need to wait for the standard process through which low-income countries apply for support to access vaccines from Gavi, the Vaccine Alliance.[6] This process would have made it possible to introduce the vaccine at the end of 2023 at the earliest.[7] However, there was another path through which these vaccines could be provided more quickly. GlaxoSmithKline (GSK), the vaccine manufacturer, had committed to donate up to 10 million vaccine doses as part of its support for the MVIP.[8] This quantity of vaccine was set aside to allow completion of the pilot program, including vaccination in the comparison areas.[9] However, additional support was needed to be able to utilize these vaccines in advance of Gavi financing, including (for example) funding to cover the costs of safe injection supplies and vaccine shipping and handling, as well as the technical assistance required to support vaccine implementation. With funding from GiveWell, PATH believed it could provide the necessary technical assistance to the ministries of health in Ghana, Kenya, and Malawi to support them in using the donated vaccines from GSK and expand vaccine access to the comparison areas at the end of 202...

Synopsis: Dr. Paul Bolno is the President and CEO of Wave Life Sciences, a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases including Duchenne muscular dystrophy and Alpha-1 antitrypsin deficiency. Paul discusses his early years at GSK and the events that led him to join Wave as CEO, and some of his early learnings during that transition from big pharma to a biotech. He also talks about the role and opportunity that RNA presents in medicine, where he sees RNA therapeutics going next, and what excites him about the emerging field of RNA editing. Biography: Dr. Bolno has served as President and CEO of Wave Life Sciences since 2013 and oversaw the company's initial public offering in 2015. During his tenure as President and CEO, Dr. Bolno has grown Wave into a fully integrated clinical-stage genetic medicines company, overseen the development of the company's proprietary stereopure oligonucleotide discovery and drug development platform, and built a broad pipeline of preclinical and clinical programs supported by scalable, in-house manufacturing capabilities. In addition to Dr. Bolno's current role at Wave, he is on the Board of Directors for SQZ Biotech and serves as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom. Prior to joining Wave, he was Vice President, Worldwide Business Development—Head of Asia BD and Investments, as well as Head of Global Neuroscience BD, at GlaxoSmithKline (GSK). He also served as a Director of Glaxo Wellcome Manufacturing, Pte Ltd. in Singapore. Dr. Bolno joined GSK as Vice President, Business Development for the Oncology Business Unit, where he helped establish GSK's global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GSK, he served as Director of Research at Two River LLC, a healthcare private equity firm. Dr. Bolno earned a medical degree from MCP-Hahnemann School of Medicine and an MBA from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.

In what is unquestionably the biggest news of the last 24 hours, former US President Donald Trump has been indicted in New York over hush money payments made to adult film actress Stephanie Clifford, also known as Stormy Daniels, who claimed she had an affair with Trump. A grand jury has voted to indict Trump, the first former US president to face criminal prosecution. Legal analysts suggest that he may be prosecuted for falsifying business records. Trump has denied the allegations and has accused Manhattan District Attorney Alvin Bragg of targeting him for political gain. Trump is also facing several other investigations, including a Georgia election interference probe and a pair of federal investigations into his role in the January 6, 2021, assault on the US Capitol by his supporters. The indictment process could take over a year, raising the possibility that the former president could face trial during or even after the 2024 presidential campaign. The average criminal case in Manhattan takes over 900 days to move from indictment to trial verdict. Trump could challenge the charges on several legal grounds, and his former personal lawyer, Michael Cohen, has stated that he coordinated with Trump on the payments to Daniels and a former Playboy model. Legal analysts suggest that the charge most likely against Trump is falsifying business records, which is typically a misdemeanor. To elevate that charge to a felony, prosecutors must prove that Trump falsified records to cover up a second crime. There is also the possibility that prosecutors could assert that the payment violated state campaign finance laws, but legal experts say that using state election law in that manner in a case involving a federal candidate is an untested legal theory. Trump could also argue that the statute of limitations of five years should have run out, but he may be unable to use serving as US president as an argument for this. According to a spokesperson for the district attorney, prosecutors and Trump's legal team are negotiating a surrender date when Trump would travel to the district attorney's office in New York to be fingerprinted and photographed.Donald Trump has been indicted - what happens now? | ReutersThe Securities and Exchange Commission (SEC) is expanding its definition of “securities dealers,” leading to a backlash from some private funds and investment advisers who fear that it will result in more regulations. The agency's proposed rule is set to clarify and expand the definition, including some financial firms such as high-frequency traders that have traditionally not been considered a dealer. Industry advocates suggest that the SEC's recent lawsuits against penny-stock flippers could further its position that a dealer is any company whose business model is based on buying and selling securities. The expanded definition of “dealer” has the potential to capture many businesses, including hedge funds and venture capital funds that are already subject to regulations. Dealers usually have to register with the SEC and join an organization like Financial Industry Regulatory Authority. Funds facing registration could change their investment strategies to avoid being labelled a dealer, according to industry representatives. However, the SEC is denying that there's anything radical about its interpretation of “dealer” and said critics are ascribing to the agency a position that it hasn't taken. SEC Pursues ‘Dealer' Definition Expansion, to Industry's DismayThe Biden administration has urged the US Supreme Court to hear the patent appeal case between Teva Pharmaceuticals USA and GlaxoSmithKline (GSK). The case involves “skinny labels”, which omit certain information from drug labels, and their potential to impact the generic-drug industry. Teva has argued that it omitted patented information for Coreg, GSK's heart drug, from its label in compliance with US Food and Drug Administration instructions. GSK sued Teva for patent infringement in 2014, with a jury siding with GSK and awarding it $235m in 2017, but the Biden administration backed Teva's argument.By way of brief background, "Skinny labels" are a term used in the pharmaceutical industry to describe labels on generic drugs that omit certain indications or uses that are covered by existing patents held by brand-name drugmakers. By using a "skinny label," generic drugmakers can launch their products earlier and avoid liability for infringing on brand-name drugmakers' patents. The US Food and Drug Administration (FDA) permits this practice, and generic drugmakers must follow strict guidelines when producing and labeling their products. However, brand-name drugmakers have sued generic drugmakers claiming that they have infringed their patents by marketing the drug for the uses not covered by the "skinny label." The aforementioned legal dispute between Teva and GlaxoSmithKline is a prime example of such a lawsuit, and the outcome of the case could have significant implications for the generic drug industry.Biden admin urges Supreme Court to hear 'skinny labels' case between Teva, GSKA court employee in New York, Dionisio Figueroa, has been accused of referring criminal defendants to a private defense lawyer in exchange for bribes. Figueroa allegedly used his position to encourage defendants, many of whom had free, court-appointed lawyers, to instead hire Telesforo Del Valle Jr. in pending cases. In return, Del Valle gave Figueroa referral payments in cash totaling at least tens of thousands of dollars. Both Figueroa and Del Valle have been charged with conspiracy to bribe a federal employee, bribery of a federal employee, and lying to federal law enforcement agents during the investigation. If you're an attorney and you don't understand what Mr. Figueroa did wrong, you might want to give your state ethic's hotline a call before you make any major decisions involving your practice. N.Y. court employee, lawyer charged with trading client referrals for cash | ReutersFinally, and very briefly, there are updates to the Disney Reedy Creek DeSantis fracas. In my other podcast, Esquiring Minds, my co-host Jacob Schumer breaks down all the ins, outs and what-have-yous of the latest. In sum, Disney may have got its revenge on Florida Governor Ron DeSantis by outmaneuvering his attempt to gain control of the Reedy Creek Improvement District that operates the 39 square mile property on which Walt Disney World exists. Before the legislation was passed, Disney quietly signed two new agreements with the district that limit what the new district can do to influence Disney's future plans. Legal scholars have said Disney may have the advantage in this situation, as the agreements are contracts that were executed in publicly noticed meetings and adhered to Florida's open government Sunshine Laws.As mentioned, please do check out Esquiring Minds, available wherever you get your podcasts – if only for the latest episode wherein Jake does a much better job explaining the story than I can. Florida attorney general demands records from former Reedy Creek membersUntangling DeSantis-Disney legal dispute could take years – Orlando SentinelDisney outmaneuvered DeSantis' new governing board, but a legal fight is brewingEsquiring Minds Podcast (@emp@esq.social)  Get full access to Minimum Competence - Daily Legal News Podcast at www.minimumcomp.com/subscribe

David W. Smith MD, ACP, BS (Chemistry), Board Certified (Internal Medicine Specialist), recognized as a visiting scientist for both The Human Performance Laboratory for the Division of Sports Medicine at Cincinnati Children's Hospital Medical Center and the North Shore Division of Neurosurgery and North Shore Neurological Institute, Chicago Illinois. Over his 30-year medical career, he served as Chief of Medicine at Reid Hospital and Healthcare Services. In addition, he founded commercial companies for developing his innovative product concepts XennovateMedical LLC, TBI Innovations LLC, and Delta Chase LLC. As Chief Science Officer, he has served as lead design and medical education consultant to GlaxoSmithKline (GSK), a $90B+ Pharmaceutical and Healthcare company, GENTEX Corp, the largest manufacturer of USAF helmets, and Materials Modification Inc., nano–materials and coating pioneer to the military complex. Consistent with his Internal Medicine credentials, Dr. Smith has Intellectual Property and peer-reviewed publications in diverse fields of science, providing him with a unique perspective in overcoming a broad spectrum of significant medical paradigms. Specifically, his solid background in analytical chemistry (with an added emphasis in physics), combined with his medical degree and internal medical career, allowed him to bring a better understanding of energy interactions and impartations to the human body, which has proven particularly useful in the study of Traumatic Brain Injury (TBI). Dr. Smith discovered and then pioneered “SLOSH Theory,” which represents the basis of his Q-Collar invention for humans designed to mitigate SLOSH energy absorption by the soft tissues of the brain, proven to reduce the risk of brain damage from traumatic events (first product authorized by the FDA for this purpose). Further, he co-authored with Julian Bailes MD, a world-renowned neurosurgeon, a presentation on “The Physics of Traumatic Brain Injury-Revisited,” delivered at the Congress of Neurological Surgeons, Annual Meeting, San Diego, CA, Sept 2016. This venue represents the largest gathering of Neurosurgeons and Brain Injury Specialists worldwide. This event provided the backdrop for Dr. Smith's disclosure of his latest thinking on how “cavitation” explains how the physics of a concussive wave can produce the chemistry of a TBI. In his scientific role with Xennovate Medical, he presented several novel battlefield dressings to the Department of the Army Research Lab (DARPA) at the Aberdeen Proving Grounds, Aberdeen, MD. Dr. Smith assisted Gentex Corp, who was successfully awarded a $90M contract in the field of mitigating the forces involved in human ejections from supersonic aircraft. He was the lead scientist in Xennovate's two-year funding effort with DARPA's Joint Improvised Explosive Device Defeat Organization (JEIDDO). Dr. David Smith stuff https://davidsmithmd.com/ https://q30.com/ Instagram: https://www.instagram.com/davidwsmithmd/ Twitter: https://twitter.com/DavidWSmithMD Facebook: https://www.facebook.com/davidwsmithmd --- Support this podcast: https://podcasters.spotify.com/pod/show/somethingsomethingpodcast/support

R. Brent Wisner serves as the managing partner of Wisner Baum (previously Baum Hedlund Aristei & Goldman) and heads up the firm's state and federal involvement with Zantac litigation. Brent personally oversees the firm's pharmaceutical class action litigation, toxic-tort injuries, and consumer fraud litigation. Wisner began gaining notoriety in 2017 after serving as Co-lead Trial Counsel in litigation against GlaxoSmithKline (GSK) for the drug Paxil, yielding a $3 million verdict. A year later, Wisner began litigation against Monsanto Roundup, earning plaintiffs over $2.424 billion in damages across three plaintiff lawsuits–and earning Brent the title of youngest attorney to earn a billion-dollar settlement.    Trial Lawyer Magazine named Brent to their 2019 list of “America's 50 Most Influential Trial Lawyers,” and National Trial Lawyers awarded him “Civil Plaintiffs Trial Lawyer of the Year.” The National Law Journal also named Brent to both 2019 lists of “America's 50 Most Influential Trial Lawyers” and “Winning Litigators, Titans of Industry.” Law360 awarded Brent the title of “MVP of the Year” in In 2020 for Products Liability and the National Law Journal and American Law Magazine inducted him into the Verdicts Hall of Fame. In 2021, Brent was awarded “West Trailblazer” by The American Lawyer, and Mass Torts Made Perfect awarded him with the “Clarence Darrow Award.” Most recently, The Litigation Counsel of America (LCA), a trial lawyer honor society, hand-picked Brent to receive the title of Associate Fellow in 2022 for his achievements as a leader across multiple dockets and his ethical commitment to plaintiff law.   Brent currently maintains heavy involvement in Ranitidine litigation (Zantac), serving as Co-Lead Plaintiffs' Liaison Counsel for the Ranitidine Product Cases (MDL No. 2924) and Co-Chair of the American Association for Justice's Zantac Litigation Group. Brent remains extremely active in the legal community and regularly presents at legal conferences, such as MTMP, AAJ, HarrisMartin and CAALA on Zantac litigation.   Brent Social Media LinkedIn -  https://www.linkedin.com/in/r-brent-wisner-94046458/ Bio - https://www.wisnerbaum.com/attorneys/r-brent-wisner/    Wisner Baum Social Media LinkedIn - https://www.linkedin.com/company/wisnerbaum/  Facebook - https://www.facebook.com/BaumHedlund  Twitter - https://twitter.com/WisnerBaum   Remember to subscribe and follow us on social media…   LinkedIn: https://www.linkedin.com/company/mass-tort-news Twitter: https://www.twitter.com/masstortnewsorg Facebook: https://www.facebook.com/masstortnews.org

On this week's episode, I am delighted to showcase the journey of a newly qualified pharmacist, Anthea Pryde. Anthea graduated from Kings College London (KCL) in 2019 and then successfully completed her trainee pharmacist year split between Lloyds Pharmacy and GlaxoSmithKline (GSK). She is currently employed as a Supply Chain Study Lead at GSK and enjoying the start of her pharmacy career. What attracted me to inviting Anthea onto the podcast was her enthusiasm and curiosity to learning and exploring what pharmacy has to offer whilst she was a student. During her life student life, she definitely made the most of the opportunities around her and she tells us all about the benefits of doing this during our conversation. Below are some of the experiences and placements she enjoyed as a student: A 3-month research internship role at Pfizer UK as part of Anthea's final year dissertation project. Project title: ‘Influence of punch tip surfaces on API adhesion' (2018) A 6-week Editorial intern at PharmPress supporting updates to the British National Formulary (BNF) and Martindale Drug Reference texts (2018) Summer Placement at Royal Brompton and Harefield NHS Foundation Trust (2018) Summer International Pharmaceutical Students Federation (IPSF) Research Internship Programme (Massachusetts College of Pharmacy and Healthcare Sciences, Boston, USA) (2017) Summer placement at Lloyds pharmacy (2016) We talk in depth about how the transferrable skills from these experiences helped her with applications and interviews, with specific reference to getting offered an industry trainee pharmacist position with very limited experience in that sector of pharmacy. Linkedin: @Anthea Pryde Follow me on YouTube, Instagram, Facebook, LinkedIn, and/or Twitter. Feel free to subscribe to the podcast on your favourite podcast platform so you can be notified when a new episode is released or leave a review on apple podcasts. If you have any suggestions for guests you want me to talk to or if you'd like to come on yourself, please feel free to contact me via social media, or email at info@pharmacistdiaries.com.

Synopsis: Amber Salzman is the CEO of Epic Bio, a company that develops therapies to dynamically control gene expression and treat complex diseases. Dr. Salzman started her career in big pharma at GlaxoSmithKline before transitioning to the biotech industry and focusing on rare diseases. In this episode, she sits down with host Rahul Chaturverdi to discuss her learnings from moving from big pharma to biotech, how her roles differ from being a CEO vs. being a board member, her perspective on pursuing interesting technology in biotech, the work Epic Bio is doing in the gene therapy space, and the role of patient advocacy in early stage biotechs. Biography: Amber Salzman, Ph.D., is Epic Bio's chief executive officer and director. Dr. Salzman is a leader with more than 30 years of experience in the pharmaceuticals industry. Before joining Epic Bio, Dr. Salzman served as the president and CEO of Ohana Biosciences, pioneering the industry's first sperm biology platform. Before Ohana, she served as the president and CEO of Adverum Biotechnologies and was a co-founder of Annapurna, SAS, where she served as president and CEO before its merger with Avalanche Biotechnologies to become Adverum. In that role, she saw the company's stock price double. Dr. Salzman began her career as a member of the GlaxoSmithKline (GSK) research and development executive team, where she was responsible for operations in drug development across multiple therapeutic areas, overseeing global clinical trials with over 30,000 enrolled patients, managing 1,600 employees and a $1.25B budget. Following her time at GSK, Dr. Salzman served as the CEO of Cardiokine, a pharmaceutical company that developed treatments for the prevention of cardiovascular diseases and saw the successful sale of the company to Cornerstone Therapeutics. Dr. Salzman currently serves on the Osler Diagnostics (UK) and AviadoBio (UK) Boards. Dr. Salzman received her bachelor's degree from Temple University and holds a Ph.D. in mathematics from Bryn Mawr College. In addition to advocating for patients living with rare diseases, Dr. Salzman leads the Stop ALD Foundation, a non-profit medical research foundation focused on developing novel gene therapies for adrenoleukodystrophy (ALD).

On this week's episode, Dan Jones welcomes Jennifer Johnson to talk GlaxoSmithKline (GSK) - they've made a good start to life post Haleon split, but are they a one-trick pony at the moment?Then Mark Robinson dives back into the Aim 100, with two more interesting stocks from our special review of the top 100 companies in Aim (by market capitalisation).And finally, Val Cipriani makes her podcast debut with a look at private equity trusts.Dan Jones hosts Jennifer Johnson, Val Cipriani and Mark Robinson.-This podcast is sponsored by TILLIT. TILLIT is the investment platform for investors who want to make better investment decisions. Invest in a curated selection of funds, investment trusts and ETFs and get expert insights on each and every one. Hosted on Acast. See acast.com/privacy for more information.

Topman Alan Jope vertrekt bij Unilever. Hij kondigde aan dat hij eind 2023 met pensioen gaat. Retailredacteur Jan Braaksma vertelt dat de achterblijvende koers van het bedrijf en de mislukte overname van de consumentendivisie van GlaxoSmithKline (GSK) voor deuken in het vertrouwen in de topman hebben gezorgd. Lees: Unilever-topman Alan Jope met pensioen na mislukte miljardenovername Het Britse pond is in een vrije val terechtgekomen. De munt stond gisteren op het laagste punt sinds 1985. De daling kwam na twijfels over de economische koers van de nieuwe Britse regering. Correspondent in het Verenigd Koninkrijk Joost Dobber vertelt dat de regering £45 mrd aan belastingverlagingen wil doorvoeren, bovenop de energiesteun die £60 mrd zal kosten. Lees: Bank of England weet val van pond niet te stoppen Nog niet zo lang geleden leek het erop dat de prijs van ruwe olie voorlopig hoog zou blijven. Maar een vat ruwe Brent-olie stond maandag kortstondig onder de $85 per vat, de laagste prijs sinds januari. Redacteur financiële markten Jeroen Groot vertelt dat de angst voor een recessie en de sterke Amerikaanse dollar de grootste oorzaken van de prijsdaling zijn. Lees: Olieprijs duikt door overschotten onder de $85 per vatSee omnystudio.com/listener for privacy information.

Wie wird das Leben nach dem Krebs? Dr. med. Woppen gibt einen Einblick in die Langzeitfolgen von Krebs. Viele Krebserkrankungen sind heute bereits heilbar und das Leben nach dem Krebs rückt immer mehr in den Fokus. Was heißt eigentlich überhaupt überleben bei einer Krebserkrankung? wenn ich länger als fünf Jahre ohne wiederkehrende Erkrankung lebe, dass ich dann davon geheilt bin? Wie erkennt man denn dann das Rezidiv und wie sieht die Nachsorge aus beim Gebärmutterkörperkrebs?GICG: https://gcigtrials.org/Studien Portal: www.studienportal-gyn.deWebseite: https://www.krebs-podcast.deSprechstunde Langzeitüberlebende: https://survivorship-clinic.de/ Referenten:Dr. med. Hannah Woopen, MSc (Fachärztin, Charité – Universitätsmedizin Berlin, Schwerpunkt: Langzeitüberleben bei Patientinnen mit Ovarialkarzinom (Studienleiterin "Carolin meets HANNA"), Junior Clinical Scientist, Master of Science - Clinical Research)Dr. med. Robert Armbrust (Oberarzt, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Charité Berlin) Erfahren Sie in dieser von vier Folgen alles zum Thema Leben mit dem Krebs. Erste Folgen zu der Serie Endometrium Karzinom: Folge 13-15. Diese Folge des Krebspodcast wird unterstützt durch GlaxoSmithKline (GSK). GSK ist jedoch nicht für den Inhalt des Vortrags verantwortlich. Thema und Inhalt obliegen der wissenschaftlichen Freiheit der Referenten.Die meisten Patienten mit Endometriumkarzinom überleben zehn Jahre, aber die Krebserkrankung ist nicht der einzige Faktor, der berücksichtigt werden muss. Nach fünf Jahren sollten keine Rezidive mehr auftreten, aber es kann vorkommen, dass nach fünf, zehn oder sogar fünfzehn Jahren doch ein Rezidiv auftritt.Die GSIG hat sich darauf geeinigt, dass Langzeitüberleben mit gynäkologischen Tumoren als Überleben von mindestens fünf Jahren gilt.Die meisten Frauen mit Endometriumkarzinom sterben nicht an Krebs, sondern an Herzkrankheiten. Es ist wichtig, dass Sie Ihre Gesundheitskompetenz stärken, um zu verhindern, dass Sie erneut an Krebs erkranken. Man sollte sich von einem Expertenteam behandeln lassen und sich auch eine zweite Meinung einholen, wenn man an Krebs erkrankt ist.Die neuen Medikamente zur Immuntherapie von Krebs werden wahrscheinlich einen großen Einfluss auf die Prognose haben, aber die Langzeitnebenwirkungen sind noch nicht bekannt.Viele Frauen, die wegen Endometriumkrebs behandelt wurden, haben Probleme mit der sexuellen Funktion, was die Lebensqualität erheblich beeinträchtigen kann. Auch Osteoporose ist eine häufige Nebenwirkung der Krebsbehandlung.Die Deutsche Krebsgesellschaft hat Verzeichnisse von Zentren, an die man sich wenden kann, und der Langzeitüberlebendenschwerpunkt in der Survivorship Klinik in Berlin ist empfehlenswert.#fernmetastasen #rezidiv #ASCO #GICG #survivorship #cancersurvivor Hosted on Acast. See acast.com/privacy for more information.

Wie wird das Leben nach dem Krebs? Dr. med. Woppen gibt einen Einblick in die Langzeitfolgen von Krebs. Viele Krebserkrankungen sind heute bereits heilbar und das Leben nach dem Krebs rückt immer mehr in den Fokus. Was heißt eigentlich überhaupt überleben bei einer Krebserkrankung? wenn ich länger als fünf Jahre ohne wiederkehrende Erkrankung lebe, dass ich dann davon geheilt bin? Wie erkennt man denn dann das Rezidiv und wie sieht die Nachsorge aus beim Gebärmutterkörperkrebs? GICG: https://gcigtrials.org/ Studien Portal: www.studienportal-gyn.de Webseite: https://www.krebs-podcast.de Sprechstunde Langzeitüberlebende: https://survivorship-clinic.de/ Referenten: Dr. med. Hannah Woopen, MSc (Fachärztin, Charité – Universitätsmedizin Berlin, Schwerpunkt: Langzeitüberleben bei Patientinnen mit Ovarialkarzinom (Studienleiterin "Carolin meets HANNA"), Junior Clinical Scientist, Master of Science - Clinical Research) Dr. med. Robert Armbrust (Oberarzt, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Charité Berlin) Erfahren Sie in dieser von vier Folgen alles zum Thema Leben mit dem Krebs. Erste Folgen zu der Serie Endometrium Karzinom: Folge 13-15. Diese Folge des Krebspodcast wird unterstützt durch GlaxoSmithKline (GSK). GSK ist jedoch nicht für den Inhalt des Vortrags verantwortlich. Thema und Inhalt obliegen der wissenschaftlichen Freiheit der Referenten. Die meisten Patienten mit Endometriumkarzinom überleben zehn Jahre, aber die Krebserkrankung ist nicht der einzige Faktor, der berücksichtigt werden muss. Nach fünf Jahren sollten keine Rezidive mehr auftreten, aber es kann vorkommen, dass nach fünf, zehn oder sogar fünfzehn Jahren doch ein Rezidiv auftritt. Die GSIG hat sich darauf geeinigt, dass Langzeitüberleben mit gynäkologischen Tumoren als Überleben von mindestens fünf Jahren gilt. Die meisten Frauen mit Endometriumkarzinom sterben nicht an Krebs, sondern an Herzkrankheiten. Es ist wichtig, dass Sie Ihre Gesundheitskompetenz stärken, um zu verhindern, dass Sie erneut an Krebs erkranken. Man sollte sich von einem Expertenteam behandeln lassen und sich auch eine zweite Meinung einholen, wenn man an Krebs erkrankt ist. Die neuen Medikamente zur Immuntherapie von Krebs werden wahrscheinlich einen großen Einfluss auf die Prognose haben, aber die Langzeitnebenwirkungen sind noch nicht bekannt. Viele Frauen, die wegen Endometriumkrebs behandelt wurden, haben Probleme mit der sexuellen Funktion, was die Lebensqualität erheblich beeinträchtigen kann. Auch Osteoporose ist eine häufige Nebenwirkung der Krebsbehandlung.Die Deutsche Krebsgesellschaft hat Verzeichnisse von Zentren, an die man sich wenden kann, und der Langzeitüberlebendenschwerpunkt in der Survivorship Klinik in Berlin ist empfehlenswert. #fernmetastasen #rezidiv #ASCO #GICG #survivorship #cancersurvivor

Rezidiv Therapie bekommt immer einen höheren Stellenwert in der Medizin. Mediziner, aber auch Sie als Angehörige und Patientinnen wissen, dass eine der Hauptsorgen bei einer Krebserkrankung ist: Kommt der Krebs wieder? Und wie wird das Rezidiv eigentlich erkannt? Deswegen wollen wir uns heute damit beschäftigen: Wie erkennt man das Rezidiv? Und was haben wir für therapeutische Möglichkeiten? Was bedeutet Immuntherapie? Ist es denn tatsächlich so, dass über die Nachsorge die meisten Rezidiv erkannt werden? Was sind was die wichtigsten und häufigsten Symptome, wie Luftnot, Schmerzen im Bein, Blutung, Nierenschmerzen, Ausfluss Studien Portal: www.studienportal-gyn.de Webseite: https://www.krebs-podcast.de Referenten: Prof. Dr. med. Dr. h.c. Sehouli (Direktor der Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie (CVK) und Klinik für Gynäkologie (CBF), Charité Berlin) Dr. med. Robert Armbrust (Oberarzt, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Charité Berlin) Erfahren Sie in dieser von vier Folgen alles Rezidiv Therapie des Gebärmutterkörperkrebses. Erste Folgen zu der Serie Endometrium Karzinom: Folge 13-14. Diese Folge des Krebspodcast wird unterstützt durch GlaxoSmithKline (GSK). GSK ist jedoch nicht für den Inhalt des Vortrags verantwortlich. Thema und Inhalt obliegen der wissenschaftlichen Freiheit der Referenten.

Rezidiv Therapie bekommt immer einen höheren Stellenwert in der Medizin. Mediziner, aber auch Sie als Angehörige und Patientinnen wissen, dass eine der Hauptsorgen bei einer Krebserkrankung ist: Kommt der Krebs wieder? Und wie wird das Rezidiv eigentlich erkannt? Deswegen wollen wir uns heute damit beschäftigen: Wie erkennt man das Rezidiv? Und was haben wir für therapeutische Möglichkeiten? Was bedeutet Immuntherapie? Ist es denn tatsächlich so, dass über die Nachsorge die meisten Rezidiv erkannt werden? Was sind was die wichtigsten und häufigsten Symptome, wie Luftnot, Schmerzen im Bein, Blutung, Nierenschmerzen, Ausfluss?Studien Portal: www.studienportal-gyn.deWebseite: https://www.krebs-podcast.deReferenten:Prof. Dr. med. Dr. h.c. Sehouli (Direktor der Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie (CVK) und Klinik für Gynäkologie (CBF), Charité Berlin)Dr. med. Robert Armbrust (Oberarzt, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Charité Berlin)Erfahren Sie in dieser von vier Folgen alles Rezidiv Therapie des Gebärmutterkörperkrebses. Erste Folgen zu der Serie Endometrium Karzinom: Folge 13-14. Diese Folge des Krebspodcast wird unterstützt durch GlaxoSmithKline (GSK). GSK ist jedoch nicht für den Inhalt des Vortrags verantwortlich. Thema und Inhalt obliegen der wissenschaftlichen Freiheit der Referenten.In dieser Podcast-Episode wird über das Rezidiv von Gebärmutterkörperkrebs und die Möglichkeiten der Therapie gesprochen Nachsorge ist wichtig, sollte länger als 5 Jahre sein, und kann viele Jahre später auftreten. Trotz aller Vorsorge, können Tumoren in der Nachsorge wieder entdeckt werden. Daher sollten Patienten mit Beschwerden nicht erst auf den Termin in der Nachsorge warten, sondern das abklären lassen. Das Wichtigste ist, dass man daran denkt, nicht alle in Panik bringt, aber dann Schritt für Schritt nach untersucht. Die Diagnose eines Tumors erfolgt in der Regel durch eine Kombination aus verschiedenen Untersuchungsmethoden, Ultraschall, Computertomografie und Magnetresonanztomografie. Die Blutwerte sind nicht immer ausschlaggebend. Untersuchungen sollten nur bei Bedarf durchgeführt werden, um Schäden durch unnötige Röntgenstrahlung zu vermeiden. Die routinemäßige Verwendung von Computertomografie bei Patientinnen, die wegen eines Tumors operiert wurden, ist sinnlos. Die Ultraschalluntersuchung des Bauches und der und über die Scheide sollten Standard sein. Die Immuntherapie ist ein großes Thema, weil wir immer mehr lernen, dass das Immunsystem nicht nur die klassischen weißen Blutkörperchen sind, sondern alle Zellen, die letztlich mehr oder weniger das Immunsystem mit positiv beeinflussen, direkt und indirekt. Inzwischen kann man bei vielen Tumoren, inklusive Gebärmutterkörperkrebs, eine chemotherapiefreie Therapiestrategie anwenden. Immuntherapie ist eine neue Art der Krebstherapie, die das Immunsystem des Patienten gegen den Krebs richtet die auch in der Behandlung von Hautkrebs wie auch bei anderen Tumoren, inklusive Gebärmutterkörperkrebs eine Revolution ist. Es gibt verschiedene Arten der Immuntherapie, die für verschiedene Situationen zugelassen sind. Ob eine Person für eine bestimmte Art der Immuntherapie geeignet ist, hängt von verschiedenen Faktoren ab. Dazu sind Studien auch bei Ersttherapie im Gange. Hosted on Acast. See acast.com/privacy for more information.

The CPI report shows that food isn't moving down as quickly as hoped, says James Locke. He discusses the chances of a full point rate hike next week. He also asks if there could be a market rally after the Fed raises rates. He also talks about how inflation is going down slowly but it is going down. He then goes over some of his stocks to watch which include GlaxoSmithKline (GSK), Bank of New York (BK), and Conagra (CAG). Tune in to find out more about the stock market today.

Gebärmutterkörperkrebs kann einen sehr beunruhigenden und verwirrenden Zeitpunkt darstellen. Viele Patientinnen haben viele Fragen und wissen nicht, wo sie anfangen sollen. Patientinnen fragen sich oft, was sie selbst machen können, um die Behandlung zu unterstützen. Wie findet man eigentlich das richtige Zentrum? Wo finde ich Informationen über Studien zum Gebärmutterkörperkrebs. In dieser Podcastfolge möchten wir einige Tipps und Hinweise geben, worauf Sie vor und während einer Krebstherapie achten sollten. Dazu gehört zum Beispiel, sich über die verschiedenen Behandlungsmöglichkeiten zu informieren und herauszufinden, welche für Sie die Beste ist. Sie sollten auch einen Ernährungsplan erstellen, um sicherzustellen, dass Sie während der Behandlung ausreichend Nährstoffe zu sich nehmen. Alle Disziplinen in den Behandlungsplan einbeziehen. Studien Portal: www.studienportal-gyn.de Webseite: www.krebs-podcast.de Referenten: Prof. Dr. med. Dr. h.c. Jalid Sehouli (Direktor der Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie (CVK) und Klinik für Gynäkologie (CBF), Charité Berlin) Dr. med. Robert Armbrust (Oberarzt, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Charité Berlin) Erfahren Sie in dieser von vier Folgen alles über alles über die Vorbereitung auf die Therapie des Gebärmutterkörperkrebses. Erste Folge der Gebähmutterkrebs-Serie über die neuesten Entwicklungen in der Diagnostik und Therapie des Gebärmutterkörperkrebses. Diese Folge des Krebspodcast wird unterstützt durch GlaxoSmithKline (GSK). GSK ist jedoch nicht für den Inhalt des Vortrags verantwortlich. Thema und Inhalt obliegen der wissenschaftlichen Freiheit der Referenten.

Gebärmutterkörperkrebs kann einen sehr beunruhigenden und verwirrenden Zeitpunkt darstellen. Viele Patientinnen haben viele Fragen und wissen nicht, wo sie anfangen sollen. Patientinnen fragen sich oft, was sie selbst machen können, um die Behandlung zu unterstützen. Wie findet man eigentlich das richtige Zentrum? Wo finde ich Informationen über Studien zum Gebärmutterkörperkrebs. In dieser Podcastfolge möchten wir einige Tipps und Hinweise geben, worauf Sie vor und während einer Krebstherapie achten sollten. Dazu gehört zum Beispiel, sich über die verschiedenen Behandlungsmöglichkeiten zu informieren und herauszufinden, welche für Sie die Beste ist. Sie sollten auch einen Ernährungsplan erstellen, um sicherzustellen, dass Sie während der Behandlung ausreichend Nährstoffe zu sich nehmen. Alle Disziplinen in den Behandlungsplan einbeziehen. Studien Portal: www.studienportal-gyn.deWebseite: www.krebs-podcast.de Referenten:Prof. Dr. med. Dr. h.c. Jalid Sehouli (Direktorder Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie (CVK) undKlinik für Gynäkologie (CBF), Charité Berlin)Dr. med. Robert Armbrust (Oberarzt, Klinik fürGynäkologie mit Zentrum für onkologische Chirurgie, Charité Berlin) Erfahren Sie in dieser von vier Folgen alles über alles über die Vorbereitung auf die Therapie des Gebärmutterkörperkrebses.Erste Folge der Gebähmutterkrebs-Serie über die neuesten Entwicklungen in der Diagnostik und Therapie des Gebärmutterkörperkrebses. Diese Folge des Krebspodcast wird unterstützt durch GlaxoSmithKline (GSK). GSK ist jedoch nicht für den Inhalt des Vortrags verantwortlich.Thema und Inhalt obliegen der wissenschaftlichen Freiheit der Referenten. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

Original Air Date 3/16/2022 — Dr. Tania Small is the Vice President and Global Medical Oncology Head at GSK. She started her career as a pediatric oncologist and realized that her passion for helping patients would drastically accelerate by transitioning to the R&D side of healthcare. She did just that, as you'll hear in this episode when she describes how it felt to see her first FDA-approved medication prescribed to treat thousands more patients than she could have ever helped individually. Her latest passion is serving the GYN/ONC research community and sharing with Matthew the many new challenges and opportunities industry is tackling head-on to put the patient more at the center of care. Also, what role can women take in getting ahead of these diseases, and how can we collaborate to help patients survive and thrive? Also, what does she see as the most revolutionary biotech innovations on the horizon for women living with cancer? Medical progress can only do so much if patients have trouble accessing care, and Covid-19 has made us painfully aware of the racial and socioeconomic gaps in healthcare access. How do we break down those access barriers and help underserved communities get the services they need?For more information, visit https://OffScrip.com and follow @MatthewZachary, and @OffScripHealth on Twitter.This ad-free episode of Out of Patients is made possible by our partner, GlaxoSmithKline(GSK), a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better, live longer. For more information, please visit https://www.gsk.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Gebärmutterkörperkrebs ist nach dem Brustkrebs die zweithäufigste Krebsart, die vorwiegend Frauen im reproduktiven Alter betrifft. Durch die Tatsache, dass wir Menschen immer älter werden und letztlich auch immer weniger bewegen, nimmt auch die Zahl der Frauen mit Gebärmutterkörperkrebs deutlich zu. Die Inzidenz ist steigend auf 11.000 Neuerkrankungen pro Jahr. Die Diagnose, Therapie und Nachsorge des Gebärmutterkörperkrebses sind komplex und bedürfen einer sorgfältigen Planung. In diesem Podcast geben Dr. med. Robert Armbrust (Link) und Prof. Dr. med. Dr. h.c. Jalid Sehouli (Link) einen Überblick über die entscheidenden Fragen in der Diagnostik, Therapie und Nachsorge des Endometriumkarzinom. Wir erleben durch die neuen Immuntherapien eine ganz neue Dynamik in der Behandlungsstrategie beim Gebärmutterkörperkrebs. Wo der Gebärmutterhalskrebs ist in Deutschland durch eine Vorsorgeuntersuchung Screening Untersuchung gut abgedeckt ist, erkennt man den Gebärmutterkörperkrebs an bestimmten Leitsymptomen. Gerade in der Therapie ist eine Abwägung von Strahlen, Chemo oder Immuntherapie je nach Risikogruppe unerlässlich. Unter anderem legen wir auch ein Hauptaugenmerk auf die Nachsorge, die gerade bei Gebärmutterkörperkrebs Patientinnen mit einem Nachsorge Konzept durchdacht sein sollte. Webseite: www.krebs-podcast.de Referenten: Prof. Dr. med. Dr. h.c. Jalid Sehouli (Direktor der Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie (CVK) und Klinik für Gynäkologie (CBF), Charité Berlin) Dr. med. Robert Armbrust (Oberarzt, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Charité Berlin) Erfahren Sie in dieser von vier Folgen alles über die neuesten Entwicklungen in der Diagnostik und Therapie des Gebärmutterkörperkrebses. Diese Folge des Krebspodcast wird unterstützt durch GlaxoSmithKline (GSK). GSK ist jedoch nicht für den Inhalt des Vortrags verantwortlich. Thema und Inhalt obliegen der wissenschaftlichen Freiheit der Referenten. Hosted on Acast. See acast.com/privacy for more information.

Gebärmutterkörperkrebs ist nach dem Brustkrebs die zweithäufigste Krebsart, die vorwiegend Frauen im reproduktiven Alter betrifft. Durch die Tatsache, dass wir Menschen immer älter werden und letztlich auch immer weniger bewegen, nimmt auch die Zahl der Frauen mit Gebärmutterkörperkrebs deutlich zu. Die Inzidenz ist steigend auf 11.000 Neuerkrankungen pro Jahr. Die Diagnose, Therapie und Nachsorge des Gebärmutterkörperkrebses sind komplex und bedürfen einer sorgfältigen Planung. In diesem Podcast geben Dr. med. Robert Armbrust (Link) und Prof. Dr. med. Dr. h.c. Jalid Sehouli (Link) einen Überblick über die entscheidenden Fragen in der Diagnostik, Therapie und Nachsorge des Endometriumkarzinom. Wir erleben durch die neuen Immuntherapien eine ganz neue Dynamik in der Behandlungsstrategie beim Gebärmutterkörperkrebs. Wo der Gebärmutterhalskrebs ist in Deutschland durch eine Vorsorgeuntersuchung Screening Untersuchung gut abgedeckt ist, erkennt man den Gebärmutterkörperkrebs an bestimmten Leitsymptomen. Gerade in der Therapie ist eine Abwägung von Strahlen, Chemo oder Immuntherapie je nach Risikogruppe unerlässlich. Unter anderem legen wir auch ein Hauptaugenmerk auf die Nachsorge, die gerade bei Gebärmutterkörperkrebs Patientinnen mit einem Nachsorge Konzept durchdacht sein sollte.Webseite: www.krebs-podcast.deReferenten:Prof. Dr. med. Dr. h.c. Jalid Sehouli (Direktor der Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie (CVK) und Klinik für Gynäkologie (CBF), Charité Berlin)Dr. med. Robert Armbrust (Oberarzt, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Charité Berlin)Erfahren Sie in dieser von vier Folgen alles über die neuesten Entwicklungen in der Diagnostik und Therapie des Gebärmutterkörperkrebses. Diese Folge des Krebspodcast wird unterstützt durch GlaxoSmithKline (GSK). GSK ist jedoch nicht für den Inhalt des Vortrags verantwortlich. Thema und Inhalt obliegen der wissenschaftlichen Freiheit der Referenten. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

Cyber Senate had the privilege of catching up with Willi Nelson, CISO, Operational Technologies, Fortinet to discuss their forthcoming presentation on Cyber Preparedness September 29-30th in Celebration Florida, for the 9th annual Control System Cybersecurity USA conference.  Large or small, cyberattacks are making headlines and elevating executive attention toward cyber resiliency. Preparing for, responding to and recovering from cyberattacks should be a strategic part of any business continuity plan. As recent cyberattacks have demonstrated increased risk to both IT and operational technology (OT) environments, readiness equates to enforcement of rules and policies that provide the visibility, control and situational awareness to respond at the speed of business.  Cybercriminals are maximizing their opportunity by exploiting older vulnerabilities and an expanding attack surface. Strategic readiness should be underpinned with the notion that eventually an attack will happen, and when it occurs, you are proactively ready to respond. During this session, we will explore security considerations for developing cyber resilience covering security fundamentals and readiness planning to protect your IT and OT environments.Willi joined Fortinet as the CISO for Operational Technology in August 2022. He brings more than 25 years of experience in Information Security working across industry verticals such as Healthcare, Telecom, Financials, Manufacturing, and Life Sciences. Most recently with GlaxoSmithKline (GSK), he established and directed the Global OT Infrastructure Security team charged with monitoring and protecting the OT assets for GSK. Globally, the team deployed 43 additional controls across the OT landscape assessed against NIST CSF and aligned business units to embrace a unified model for security, incident response, and risk reporting. During Willi's tenure, he also oversaw the creation of the Security Organization and the Global Cyber Defense team for GSK's Consumer Health startup (now called Haleon). Beyond building and leading the OT and Consumer Health security teams, he led the security team responsible for Cloud transformation for both IT and OT. Willi relies on a pragmatic and systematic approach to achieve company goals while also maturing the organizations and teams he leads. Willi is a graduate of Rockhurst University in Kansas City, MO, USA and holds a CISSP (Certified Information Security Professional) certification in good standing. Willi lives in NW Arkansas with his family. He's an avid outdoorsman, cyclist, woodworker, and veteran.

Highlights of my conversation with Raj: Allowing teams to make decisions at the lowest possible level Empowerment is coupled with responsibility Make sure only the necessary stakeholders are in a meeting Always do the right thing for the customer and stakeholders Building out a learning culture Agile mindset shift Failing faster requires empowerment Focusing on measuring outcomes and not activities Meet: Raj Madan has over 20 years of digital transformation and innovation experience and is currently the CDIO at Arcutis Biotherapeutics. Before joining Arcutis, Raj served as the Vice President of Digital, Data/Analytics, and Innovation for Consumer Healthcare Technology at GlaxoSmithKline (GSK). In partnership with the Chief Digital Officer, he was responsible for driving significant elements of their Digital and Tech transformation globally. Before GSK, Raj was with Novartis. He was responsible for managing and delivering global, regional, and localized digital solutions and services across three business units and in more than 80 countries. In addition to healthcare, Raj has experience in the consumer goods sector, having spent 14 years at L'Oreal in various roles, including managing the digital tech function for L'Oreal Americas. Raj holds a bachelor's degree in computer engineering from the New Jersey Institute of Technology and a master's degree in business administration and information systems from New York University Stern School of Business. Raj is also an advisory board member at Onymos, an app development platform that helps developers and teams build brilliant apps faster. If you have any questions for Raj, please feel free to reach out via: https://www.linkedin.com/in/rajvir-raj-madan-3a74252 I hope you enjoyed the episode. The best place to connect with me is on Linkedin - https://www.linkedin.com/in/amirbormand (Amir Bormand). Please message me if you want me to cover specific topics with future guests.

Bijan Esfandiari serves as Senior shareholder at Baum Hedlund Aristei & Goldman, litigating cases of pharmaceutical product liability. Bijan discusses his current MDL (No. 3036) against pharmaceutical company Merck for the production and distribution of Gardasil, an HPV vaccine believed to cause POTS. Esfandiari explains how the defense shames victims of the toxic vaccine into silence by labeling them “anti-vaxers.” Esfandiari also actively worked on the 2010 GlaxoSmithKline (GSK) litigation, which resulted in $750 million settlement in civil and criminal claims over the company's manufacturing of contaminated medication. Esfandiari received a unanimous agreement from a three-judge panel for his arguments in both the McCormick v. Medtronic, Inc. and Mason v. SmithKline Beecham Corp. With over 20 years of experience in law, Esfandiari holds great passion for helping others, specifically those harmed by large corporations. Bijan's most recent honors include being named to the 2022 of Best Lawyers in America®, Lawdragon's 2022 list of Leading Plaintiff Consumer Lawyers, and Law360's 2021 series of Regional Powerhouses in California. Bijan also received recognition on the Southern California Super Lawyers® list of Rising Stars annually since 2009. Esfandiari remains active in the law community outside of the courtroom by speaking at national law conferences and serving as a member of the pro-bono Representative Assembly of the Palms Neighborhood Council. Bijan maintains membership in the American Association for Justice's Leader's Forum, the Consumer Attorneys Association of Los Angeles, and UCLA Journal of International Law & Foreign Affairs. Bijan speaks fluent Farsi and conversational German.  Remember to subscribe and follow us on social media… LinkedIn: https://www.linkedin.com/company/mass-tort-news Twitter: https://www.twitter.com/masstortnewsorg Facebook: https://www.facebook.com/masstortnews.org

Dr. Amber Salzman, Ph.D. is Chief Executive Officer and Director of Epic Bio (https://epic-bio.com/), a fascinating therapeutic epigenome editing startup, developing therapies to modulate gene expression at the level of the epigenome, which just recently emerged from stealth mode with a $55 million funding round. Dr. Salzman has more than 30 years of experience in the pharmaceuticals industry. Before joining Epic Bio, Dr. Salzman served as the president and CEO of Ohana Biosciences, pioneering the industry's first sperm biology platform. Before Ohana, she served as the president and CEO of Adverum Biotechnologies and was a co-founder of Annapurna, SAS, where she served as President and CEO before its merger with Avalanche Biotechnologies to become Adverum. In that role, she saw the company's stock price double. Dr. Salzman began her career as a member of the GlaxoSmithKline (GSK) research and development executive team, where she was responsible for operations in drug development across multiple therapeutic areas, overseeing global clinical trials with over 30,000 enrolled patients, managing 1,600 employees and a $1.25B budget. Following her time at GSK, Dr. Salzman served as the CEO of Cardiokine, a pharmaceutical company that developed treatments for the prevention of cardiovascular diseases and saw the successful sale of the company to Cornerstone Therapeutics. Dr. Salzman currently serves on the Osler Diagnostics (UK) and AviadoBio (UK) Boards. Dr. Salzman received her bachelor's degree from Temple University in computer science and holds a Ph.D. in mathematics from Bryn Mawr College. In addition to advocating for patients living with rare diseases, Dr. Salzman leads the Stop ALD Foundation, a non-profit medical research foundation focused on developing novel gene therapies for adrenoleukodystrophy (ALD).

La empresa farmacéutica británica GlaxoSmithKline (GSK) abrirá en Uruguay en los "próximos dos meses" uno de sus "tres nuevos centros regionales de distribución de vacunas", donde se colocarán más de "12 millones de vacunas al año en seis países de América del Sur", así dice declaración conjunta entre Reino Unido y Uruguay que informó el Ministerio de Relaciones Exteriores este martes, un día después del encuentro que mantuvieron Luis Lacalle Pou y Boris Johnson. El comunicado de Cancillería indica que tanto Lacalle Pou y Johnson "señalaron el enorme potencial de crecimiento de los vínculos comerciales y económicos y celebraron el anuncio de GSK sobre la apertura de uno de sus tres nuevos centros regionales de distribución de vacunas en Uruguay". "Este centro será inaugurado en los próximos dos meses, y desde el mismo se distribuirán más de 12 millones de vacunas al año en 6 países de América del Sur", agrega el comunicado, que no aporta más detalles de esta inversión. ¿Dónde estará este centro de GSK? En las instalaciones de Latin America Cargo City (LACC), la unidad de negocios que maneja las cargas de Corporación América en el predio del aeropuerto de Carrasco. Profundizamos en esta novedad y lo que ocurre en el aeropuerto. Conversamos En Perspectiva con Bruno Güella, CEO de Latin America Cargo City (LACC).

- Sáng nay (11/5), tại TPHCM, Tập đoàn dược phẩm hàng đầu Thế giới GlaxoSmithKline - GSK (Bỉ) và Hệ thống trung tâm tiêm chủng VNVC đã ký kết biên bản ghi nhớ hợp tác chiến lược toàn diện và lâu dài về cung ứng vắc xin, mở ra cơ hội để VNVC đưa về Việt Nam nhiều loại vắc xin mới, vắc xin khan hiếm với số lượng lớn tiêm chủng cho người dân. --- Support this podcast: https://anchor.fm/vov1tintuc/support

Will inflation return to normal in 2024, and will a recession occur? Value stocks outperformed growth stocks in April. M&T Bank (MTB) stock price is up almost 5% year-to-date. "M&T Bank recently acquired Peoples Bank. Will the company raise expectations following the merger? MTB reported above-consensus results," says James Locke. Also, the GlaxoSmithKline (GSK) stock price is up over 13% this past year. "The pharmaceutical and healthcare products company trades at 14.6X 2022 EPS and pays a 5.3% dividend rate. The company expects mid-single-digit sales growth and high single to low double-digit EPS growth going forward," Locke adds.

This week, we're joined by Valentino Parravicini, Chief Scientific Officer at Oxford Cannabinoid Technologies - British pharmaceutical company developing a portfolio of next-generation prescription cannabinoid medicines.In this episode, we explore the potential use of cannabis-based medicines as a replacement for prescription opioids, their safety profile, and their use cases as analgesics. 

Dr. Tania Small is the Vice President and Global Medical Oncology Head at GSK. She started her career as a pediatric oncologist and realized that her passion for helping patients would drastically accelerate by transitioning to the R&D side of healthcare. She did just that, as you'll hear in this episode when she describes how it felt to see her first FDA-approved medication prescribed to treat thousands more patients than she could have ever helped individually. Her latest passion is serving the GYN/ONC research community and sharing with Matthew the many new challenges and opportunities industry is tackling head-on to put the patient more at the center of care. Also, what role can women take in getting ahead of these diseases, and how can we collaborate to help patients survive and thrive? Also, what does she see as the most revolutionary biotech innovations on the horizon for women living with cancer? Medical progress can only do so much if patients have trouble accessing care, and Covid-19 has made us painfully aware of the racial and socioeconomic gaps in healthcare access. How do we break down those access barriers and help underserved communities get the services they need? This ad-free episode of Out of Patients is made possible by our partner, GlaxoSmithKline(GSK), a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better, live longer. For more information, please visit https://www.gsk.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Unilever staat al een tijdje onder druk. Onder het tienjarige regime van Paul Polman bleven de winsten hopeloos achter bij de concurrentie. Zijn duurzame missie klonk destijds erg sympathiek, maar leverde geen winst op. Zijn opvolger, Alan Jope, heeft daar nog geen verandering in kunnen brengen. De golf van kritiek onder beleggers zwol steeds verder aan, en dat is in de koers terug te zien: die is flink bij de sectorgenoten achtergebleven. Het management besloot daarom een grote sprong voorwaarts te maken. Het deed een bod van £50 mrd op de consumententak van GlaxoSmithKline (GSK) - terwijl Unilever zelf slechts £100 mrd waard is - en ook nog eens tegen een superwaardering. De analistenramingen die ik voorbij zag komen, geven een GSK-waardering die ongeveer 50% hoger is dan die van Unilever. Dat leidt tot een enorme verwatering en dat werd gelijk ingeprijsd: het aandeel kelderde aanzienlijk. Beleggers vreesden nog hogere biedingen, maar haalden opgelucht adem toen Unilever aangaf dat £50 mrd wel even genoeg was. De kans dat de deal nu nog doorgaat, wordt erg klein geacht. Hoe wilde Unilever deze deal eigenlijk succesvol maken? In eerste instantie door kostenbesparingen. Die mogelijkheden lijken mij beperkt, GSK wordt al redelijk efficiënt gerund. Samen met GSK zou Unilever tandpastakoning worden. Maar hoe kun je die positie als marktleider uitnutten? Hoeveel kosten wil je hiermee besparen? Omzetsynergieën zijn er ook beperkt. Het voordeel moet vooral uit de financiële hefboom komen. Als je leent tegen bijna 0% rente, werkt dat al snel. De schuldratio gaat dan van twee keer het bedrijfsresultaat naar vier keer. Dan ben je eigenlijk een beetje private equity aan het spelen. Natuurlijk zou Unilever een deel van de overgenomen activiteiten weer doorverkopen. Maar als je iets heel graag wil hebben, dan betaal je de hoofdprijs. En als je dan later iets graag kwijt wil, gaat dat meestal tegen een discount. Iedereen weet immers dat je moet verkopen. Wat me overigens wel aan deze dealaankondiging opviel, is de bescheiden interesse van de media. Als Unilever nog Nederlands was geweest, dan zou het op alle voorpagina's hebben gestaan. Nu stond het ergens op pagina 16. Het is duidelijk dat Nederland emotioneel afscheid heeft genomen van Unilever, en voor beleggers geldt hetzelfde. Of de deal uiteindelijk doorgaat of niet, deze move brengt de magere operationele prestaties voor het voetlicht. Er zijn overigens partijen die wel graag dit soort berichten lezen. Voor Unilever is het spel op de wagen. De grote private-equitypartijen zullen hun spreadsheets laten ratelen. Ik ben benieuwd of de uitkomsten interessant genoeg zijn. Over de column van Corné van Zeijl Corné van Zeijl is analist en strateeg bij vermogensbeheerder Actiam en belegt ook privé. Reageer via corne.vanzeijl@actiam.nl. Deze column kun je ook iedere donderdag lezen in het FD.See omnystudio.com/listener for privacy information.

❗⁠您的一杯咖啡錢 = 我們遠大的目標！捐款支持我們：https://pse.is/3jknpx

A tremendous interview that gives some insight to the highs and lows of 2021. What companies and Andy have learned through Covid. The hunt for disrupters. Activists and bid activity. The attractions of the FTSE100. We hear how an institution exits a position. The attractiveness of an IPO, a placing or an overhang. Director buys and sells. Latterly, we discuss bitcoin and NFT's (Non Fungible Tokens). Finally, for those who want the investing challenge (or fancy themselves as a Fund Manager!), we discuss the new PIWORLD series, Sell it to the City, and what the Fund Managers, Andy, Judith and Stephen are looking for from contestants. Please contact PIWORLD.CO.UK if you want to take part. A very engaging and informative listen. Thank you Andy! 01:02 How has 2021 been? 01:46 Omicrom? 03:28 Views on a Santa rally? 05:18 Inflation 07:05 Tapering 08:17 Disrupters Reach #RCH, Future #FUTR, Lookers #LOOK, Inchcape #INCH 12:15 Property - Grainger #GRI 13:11 FTSE100, FTSE250 v AIM Royal Mail #RMG; Land Securities #LAND; #WISE, Marks & Spencer #MKSN 17:18 Activists: Elliot, Glaxosmithkline #GSK, Taylor Wimpey #TW., Clinigen #CLIN, Pearson #PSON, Johnson Matthey #JMAT 17:50 Which holdings which will move the dial? Frasers #FRAS, Studio Retail #STU 19:00 Bid activity Clinigen #CLIN 19:47 Studio Retail #STU 22:43 Learnings from 2021 25:22 Tremor #TRMR 26:47 Bid pick for 2022 Indivior #INDV 28:39 Crystal Amber and selling an overhang #DLAR 30:57 Institutional pools of liquidity & IPOs 32:18 Preference to buy and IPO, placing or overhang? 34:18 Evolution of Covid: what went well and what went badly 37:44 Director buys and sells Telecom Plus #TEP; Tremor #TRMR Fraser #FRAS 40:19 Bitcoin 41:40 NFTs 42:14 Where to find Andy Brough & his funds 42:41 Sell it to the City: what is it? What the Fund Managers want to hear. (Sell it to the City - Episode 1: https://www.piworld.co.uk/education-videos/piworld-sell-it-to-the-city-october-2021/) About Andy Brough: • Head of the UK & European Small and Mid Cap team • Manager of the Schroder Mid 250 Fund and the Schroder UK Smaller Companies Fund • Co-Manager of the Schroder UK Mid Cap Fund plc and Co-manager of the Schroder Institutional UK Smaller Companies Fund • Co-manager of Schroder ISF European Smaller Companies • Investment career commenced on joining Schroders in 1987 • Chartered Accountant • BSc in Economics, Manchester University https://www.schroders.com/

Back in action, in this weeks episode of the Bank On Dividends Podcast, Banky takes a deeper look into the Pharmaceutical giant Glaxo Smith Kline: Ticker "GSK". Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world's sixth-largest pharmaceutical company. In August 2016, it had a market capitalisation of £81 billion (about US$107 billion), the fourth largest on the London Stock Exchange. But is GSK a stock to consider when building a portfolio you can bank on! Follow on Instagram and Twitter @BankOnDividends https://linktr.ee/BankOnDividends Use the above link for a free share & Also support the Podcast with a one-time donation! Thank You All!

Por unanimidade, a Agência Nacional de Vigilância Sanitária (Anvisa) aprovou o uso emergencial do Sotrovimabe, um anticorpo monoclonal, fabricado pela GlaxoSmithKline (GSK), contra a Covid-19. O monitor Caio Mello (do curso de Jornalismo) explica o que é o medicamento e a forma como ele será administrado. Além disso, ele diz quantos focos de incêndio foram registrados no Cerrado brasileiro no período de 1º de janeiro a 31 de agosto, segundo dados do Programa de Queimadas do Instituto Nacional de Pesquisas Espaciais (Inpe), e as consequências nacionais que o problema pode gerar.

Nadir Pop and Peter Pop are back with another episode of Entrepreneur parent with guest, Pooja Sardana. A graduate of IIM - Ahmedabad, Pooja worked at GlaxoSmithKline (GSK) and Hindustan Lever Ltd. before turning entrepreneur with Skoodo. Pooja shares with the Pop duo the origins of Skoodo, the differences between shoes for kids and adults, her experience traveling to over 30 countries with her children and more. Get in touch with the Pops with feedback, questions and more on popsinapod@gmail.com Follow Pops In A Pod Instagram - https://www.instagram.com/popsinapod/ Facebook - https://www.facebook.com/popsinapod Youtube - https://www.youtube.com/channel/UCP3CLTlZuCc9WqgiHjhJ_AQ Nadir currently leads the Business Development division at a digital agency. Prior to this Nadir spent a decade in TV and digital video production – producing, directing, developing content and writing. www.linkedin.com/in/nadir-kanthawala-47249814/ Peter is a marketing guy. He has a decade experience working with companies ranging from startups to public listed companies. www.linkedin.com/in/peterkotikalapudi

A digital twin is a virtual representation that serves as the real-time digital counterpart of a physical object or process. Biopharma giant GlaxoSmithKline (GSK) has adopted this technology to advance its vaccine development and manufacturing division. A year after partnering with Siemens and Atos to pilot a digital twin in order to create a real-time simulation of the entire vaccine manufacturing process, we sat down (virtually, sadly) with Matt Harrison, head of Sciences, Digital Innovation and Business Strategy at GSK to discuss the current status of this project.   Keep up with BioProcess Insider on our website. Follow us on LinkedIn and Twitter: @BioProInsider @BioProcessIntl @Dan5tanton

Carlos Santiago began his career in GlaxoSmithKline (GSK) as a Site Utilities Engineer at their Manufacturing facility in Cidra, Puerto Rico. With more than twelve years at GSK, he held several roles of increasing responsibility in both the Global Manufacturing & Supply (GMS) and Worldwide Real Estate and Facilities (WREF) organizations. Carlos led the Hispanic/Latino Employee Network (“Conexion Latina”) at GSK which was recognized by Diversity Best Practices in 2018 for their work and impact on hurricane relief efforts in Puerto Rico. His different roles have allowed him to work in many locations as well as travel to more than 30 countries in 4 continents. Carlos is part of the CoRE Tech Advisory Board. He is a graduate of the University of Puerto Rico with a Bachelor of Science in Electrical Engineering and holds a MBA from Universidad del Turabo. When he is not working, he enjoys reading, traveling and running. Carlos is married to Lourdes and has three children; Noah, Gabriella and Carlos Jr. Learn more about GSK here Shout-out: Today's Diversity Leader Shout-out goes to Maya Martinez-Davis, President, U.S. Pharmaceuticals, GSK Music: Intro - Vente by Mamá Patxanga is licensed under a Attribution-Noncommercial-Share Alike 3.0 United States License Outro - Amor Y Felicidad by SONGO 21 is licensed under a Attribution-NonCommercial-ShareAlike 3.0 International License --- Send in a voice message: https://anchor.fm/si-suite/message

Carlos Santiago began his career in GlaxoSmithKline (GSK) as a Site Utilities Engineer at their Manufacturing facility in Cidra, Puerto Rico. With more than twelve years at GSK, he held several roles of increasing responsibility in both the Global Manufacturing & Supply (GMS) and Worldwide Real Estate and Facilities (WREF) organizations. Carlos led the Hispanic/Latino Employee Network (“Conexion Latina”) at GSK which was recognized by Diversity Best Practices in 2018 for their work and impact on hurricane relief efforts in Puerto Rico. His different roles have allowed him to work in many locations as well as travel to more than 30 countries in 4 continents. Carlos is part of the CoRE Tech Advisory Board. He is a graduate of the University of Puerto Rico with a Bachelor of Science in Electrical Engineering and holds a MBA from Universidad del Turabo. When he is not working, he enjoys reading, traveling and running. Carlos is married to Lourdes and has three children; Noah, Gabriella and Carlos Jr. Learn more about GSK here Shout-out: Today's Diversity Leader Shout-out goes to Maya Martinez-Davis, President, U.S. Pharmaceuticals, GSK Music: Intro - Vente by Mamá Patxanga is licensed under a Attribution-Noncommercial-Share Alike 3.0 United States License Outro - Amor Y Felicidad by SONGO 21 is licensed under a Attribution-NonCommercial-ShareAlike 3.0 International License --- Send in a voice message: https://anchor.fm/si-suite/message

I Never Trusted Bill Gates, Nor Should You While leading a Senate investigation, I tracked a corrupt pharmaceutical executive right into the lobby of the much-vaunted Bill and Melinda Gates Foundation—Bill Gates did nothing.   The DisInformation Chronicle,   https://disinformationchronicle.substack.com/p/i-never-trusted-bill-gates-nor-should   The last year has not been kind to Bill Gates.  For two decades, Gates has shoveled out buckets of cash through the Bill and Melinda Gates Foundation to transform himself from despised 1990’s software monopolist to a present-day public health intellectual—a miraculous, money-fueled metamorphosis. But that reputational makeover has stumbled, as a series of critical articles have tarnished Gates’ paid-for golden image and cast doubt on his credibility. However, long before these articles came to light, I already knew that Gates could not to be trusted.  A decade ago, I led a Senate investigation into a multi-billion-dollar diabetes drug sold by GlaxoSmithKline (GSK) that government scientists found to have caused around 83,000 heart attacks. During this federal investigation, I uncovered multiple examples of GSK officials intimidating medical experts who decried the drug’s dangers. A leader in this campaign was GSK’s chairman of research and development, Dr. Tadataka (Tachi) Yamada.  By the time our committee uncovered GSK’s coercion campaign, Yamada had left the company to run Gates’ global health program. And yet, as the media outlets reported on Yamada’s prior role bullying physicians who tried to warn about the drug’s dangers, the Gates Foundation ignored this public outcry and allowed Yamada to maintain his pulpit as global health protector. Twenty years back, journalists scrutinized Gates’ foundation as a vehicle to enrich himself and polish his appearance. But over the years, reporters began to forget Gates’ past and provide him a platform to puff himself up as scientific expert, despite his having no medical or scientific credentials. Bill Gates’ sculpted persona as health policy guru began to wobble last summer, however, precisely because of revelations showing the tools he had used to improve his media cachet. In August 2020, Tim Schwab published an article in the Columbia Journalism Review exposing around $250 million in grants that Gates was throwing at journalism outlets including the BBC, NBC, Al Jazeera, ProPublica, National Journal, The Guardian, Univision, Medium, the Financial Times, The Atlantic, the Texas Tribune, Gannett, Washington Monthly, Le Monde, and the Center for Investigative Reporting.  A later article in The Nation spotlighted Gates’ potential to profit from investments in companies situated to reap a windfall from the COVID pandemic. And another report in The Nation found that Gates’ funding has stifled debate in public health—described as “the Bill chill”—as organizations are reluctant to bite the hand that feeds them. These revelations came as little surprise to me. Back in 2007, I was working as an investigator for the Senate Finance Committee and learned first-hand that Bill Gates does not put the public first. That year, I wrote the Senate Finance Committee’s report showing that, shortly after the GSK diabetes drug Avandia came on the market in 1999, the company attacked and silenced several scientists including Dr. John Buse, a professor of medicine at the University of North Carolina.  GSK began to bully Dr. Buse after he gave talks stating that Avandia might increase cardiovascular problems such as heart attacks. By the time we released the 2007 report, FDA scientists estimated that Avandia had caused approximately 83,000 heart attacks. When Dr. Buse began warning physicians about the drug, Dr. Yamada was at GSK and contacted Dr. Buse’s department chairman to complain. In an email discussing Dr. Buse with GSK’s CEO and other executives, Dr. Yamada wrote:  In any case, I plan to speak to Fred Sparling, his former chairman as soon as possible. I think there are two courses of action. One is to sue him for knowingly defaming our product even after we have set him straight as to the facts—the other is to launch a well planned offensive on behalf of Avandia.... In our report, we released a private email that Dr. Buse later sent a colleague detailing this encounter with GSK: [T]he company’s leadership contact[ed] my chairman and a short and ugly set of interchanges occurred over a period of about a week ending in my having to sign some legal document in which I agreed not to discuss this issue further in public. Dr. Buse ended the email, “I was certainly intimidated by them.... It makes me embarrassed to have caved in several years ago.” Multiple media outlets covered Yamada’s actions, including The Guardian (GSK accused of trying to intimidate critic), NBC News (Diabetes drug probe leads to Gates Foundation), and even Bill Gates hometown newspaper, the Seattle Times (Senate committee turns attention to Gates Foundation official). Months prior to the report’s release, The New York Times also detailed Dr. Yamada’s behavior (Doctor Says He Was Assailed for Challenging Drug’s Safety), as some initial evidence came to light during a hearing in the House.  In response to all this outcry, Bill Gates did... nothing. To put this matter directly under Bill Gates’ nose, I then wrote the Senate Committee’s letter demanding that Dr. Yamada come and brief Senate investigators. Just in case Gates was too distracted with saving the world and playing public health saviour to have noticed the bad press, I had the letter sent directly to the Gates Foundation. When Dr. Yamada showed up for his appointment in Senate Hart, we started with some brief niceties and formalities—typical DC nonsense such as shaking hands, passing out business cards, asking how the plane flight was—before getting down to business. Dr. Yamada’s lawyer then pulled from his briefcase a marked-up copy of a Committee report I had written titled: The Intimidation of Dr. John Buse and the Diabetes Drug Avandia.   We spent about twenty minutes going over the report, as the lawyer explained what Dr. Yamada had done. He then turned the matter over to Dr. Yamada to detail why, many years prior, he had called Dr. Buse's superiors at the University of North Carolina. As Dr. Yamada explained, he wasn't trying to intimidate anyone. Ironically, he even offered up the idea that he had called Dr. Buse's dean at North Carolina, because he was concerned that Avandia might actually be harmful. And if the drug was harmful, Dr. Yamada said, he wanted to know. I almost giggled when he said that. I then asked, "So this is the only time that you can remember calling a university about one of their faculty?" "Yes," he replied. I let him drone on some more, explaining medical research, before I asked him again if he had ever called a university to complain about a professor. Again, he denied doing so, and then started explaining drug development and the regulatory process at the FDA.  I then asked again, "So during all your time at GSK, this is the only incident you can remember where you placed a call to a university about a researcher who raised concerns about one of your products, correct?” I asked. “It was a singular incident in your time at the company?” "Yes," he said. This was the third time that Dr. Yamada had denied making calls to other universities to intimidate academics speaking up about Avandia. I then pulled out copies of GSK emails, showing that Dr. Yamada had called the University of Pennsylvania about physicians there who were worried about drug’s dangers. “Would you like to explain to us about the call you made to the University of Pennsylvania?” I asked. “One of the physicians involved told me, 'It left a really bad taste in my mouth. After that happened, I said that I would never work for a drug company.’ Another physician who was involved told me, 'It’s the kind of thing you imagine happening on TV.'’’ I then slid the emails across the table to him. Dr. Yamada’s attorney jumped up and grabbed the emails saying, “These emails weren't in the report!” “No shit, Counselor,” I thought. “I left these ones out, to see if your client might lie to us. Calm down. Everything's going to be A-O-K....” We then exchanged some more niceties as Yamada “reexplained himself.” Oddly enough, it seems there may have been more than just that one incident at North Carolina, Dr. Yamada said. But I really wasn't interested in listening and started checking my Blackberry. It took a couple more years to go through hundreds of thousands of GSK’s internal documents before we released our final 342-page report in 2010 titled: Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia. But we redacted the names of the scientists at the University of Pennsylvania who Dr. Yamada had harassed for speaking up, because they were still scared about possible retaliation from the drug industry.  After reading the report, Yale cardiologist Harlan Krumholz wrote that it "read like a spy novel.” Analysts at UBS predicted that GlaxoSmithKline could face legal liability of up to $6 billion. The New York Times covered the report on its front page and the CBS News put Yamada in its story’s headline: Meet Glaxo's Fixer -- The Man Who Scuttles Drug Critics With One Phone Call. And still, Bill Gates did nothing. Five months after the 2010 Senate Finance report, GSK agreed to a $460 million settlement with 10,000 Americans who sued the company for withholding Avandia’s heart attack risks. The New York Times editorialized that GSK and its leaders “can’t be trusted to report adverse clinical results fairly.”  Nothing at all happened to Yamada. He remained in his role as global health expert at the Gates Foundation, until he left the following year, in June 2011.  Keeping someone like Yamada to run a global health program has always made me doubt Bill Gates’ commitment to public health. How could anyone have faith in Gates’ judgement after watching him stand idly by as a stream of evidence proved that one of his top lieutenants had a history of corrupt behavior? Since that time, I have never trusted Bill Gates. And neither should you.

Het Randstad Employer Brand onderzoek vindt sinds 2000 plaats. Het gaat na waarom werkzoekenden kiezen voor een bepaalde werkgever. Vervolgens wordt een staal van bedrijven voorgelegd die de respondenten moeten beoordelen. Kent men het bedrijf? Zou men er al of niet graag werken? En hoe beoordelen zij het bedrijf op tien geselecteerde criteria?Het onderzoek leert hoe (on)aantrekkelijk bedrijven zijn én waarom. Het levert de bedrijven een unieke benchmark op inzake hun employer brand. Doorheen de tijd is het van oorsprong Belgisch onderzoek geëxporteerd naar 34 landen in vier werelddelen. Anno 2021 blijft het Randstad Employer Brand onderzoek het enige representatieve in dit domein.De slotsom van de vorige studie, gepubliceerd in mei 2020, luidde: “Er is geen ontkomen aan, deze crisis zal zwaar inhakken op de employer brands van bedrijven. Gezien de aard van deze crisis zal dit normaliter nog zwaarder zijn dan bij de vorige recessies.” Die pessimistische toon was gebaseerd op de resultaten in 2009 in de nasleep van de financiële crisis. Maar de gevreesde recessie met jobdestructie bleef (voorlopig) uit.De gemiddelde aantrekkelijkheidsscores blijken niet gedaald. Nagenoeg alle sectoren laten zelfs een gemiddelde stijging optekenen. Geen enkel criterium wordt lager beoordeeld dan vorig jaar. De scores liggen meestal zelfs een kleine fractie hoger. Alleen werkzekerheid blijft ter plaatse trappelen. Dit toont duidelijk aan dat er geen sprake is van een crisisgevoel.Ook de rangschikking waarom men voor een werkgever kiest, ondergaat geen wijzigingen. Werkzekerheid wordt niet belangrijker, het criterium verliest zelfs een plaats en staat nu op vier. De nieuwe coronagerelateerde criteria – thuiswerk en coronaveilig werken – halen een middenpositie. Dat betekent dat loon en voordelen nog steeds het belangrijkste criterium is, dit jaar voor werksfeer en balans werk/privé.De rangschikking van de sectoren blijft ook merkwaardig stabiel. De sectoren die meer dan gemiddeld hinder hebben ondervonden van corona (zoals horeca, toerisme en luchtvaart) houden niet alleen stand, ze gaan er inzake aantrekkelijkheid op vooruit. Dit betekent dat de respondenten de huidige problemen als tijdelijk zien. Ook naar het resultaat van farma werd uitgekeken. Zou de sector profiteren van het vaccinsucces of zou de kritiek op de sector inzake de levering van het vaccin overwegen? De positieve invloed haalt het. De farmasector is voor de twintigste keer (op 21) de meest aantrekkelijke sector. De overwinning wordt nog kracht bijgezet door een tweede plaats bij het criterium CSR. Vorig jaar was dit het enige criterium waar de sector geen top 3 haalde.Het meest verrassende resultaat komt van de luchtvaartsector, die op een zucht van de eerste plaats strandt. De mediasector moet dit jaar tevreden zijn met een derde plaats.Janssen Pharmaceutica is voor de vijfde keer in de geschiedenis van het Randstad Employer Brand onderzoek de meest aantrekkelijke werkgever. Daarmee wordt de nationale trots recordhouder voor DEME en GlaxoSmithKline (GSK), die elk vier keer wonnen.Janssen haalt het redelijk afgetekend voor de nummers twee en drie: Seris en Nike. Voor beide bedrijven is het de eerste keer dat een top 10 positie werd behaald. Nike was in 2020 wel al de meest aantrekkelijke werkgever bij de jongeren, een prestatie die dit jaar wordt herhaald. Seris is de meest aantrekkelijke werkgever in Franstalig België en onttroont RTBF. Bayer en DPG Media vervolledigen de top vijf. Verder in de top 10 valt de sterke prestatie op van Brussels Airlines, dat inzake aantrekkingskracht geen coronaschade heeft opgelopen

In today's episode, Chad sits down with guest scientists, Drs. Jolly Mazumdar and Tim Chendrimada, CEO, and CSO of Chimeron Bio. Two different beginnings; one in the sciences studying bugs and infectious diseases and the other in agriculture, specifically coffee beans! They talk to Chad about how their very different paths led them to become a dynamic duo in the next generation of RNA therapeutics. From Tim asking a scientist of Wistar Institute to take a chance on him with no prior experience in medical science to Jolly traveling to the United States for graduate studies in infectious diseases, we learn about how the pair, originally from India, carved their paths to where they are now as veterans in the Pharma industry. Both with careers early on at GlaxoSmithKline (GSK), Jolly’s focus was on biomarkers and innovative early clinical trials in skin cancer drugs and Tim’s on the development side as a bench scientist and the importance of having teamwork when it comes to drug development. These valuable experiences led them to create Chimeron Bio. They talk about how the opportunity to create Chimeron Bio came to be, the importance of challenging yourself and taking risks you believe in, talking to investors, their technology pipeline and self-amplifying RNA COVID-19 vaccine that protects against new variants. See omnystudio.com/listener for privacy information.

Ngành sản xuất vac-xin nhờ virus corona lãi bạc tỷ. Chìa khóa của đà phục hồi kinh tế cho thế giới sau hơn một năm chống chọi với đại dịch Covid-19 trong tay một số rất ít các viện bào chế. Không dễ tìm ra một loại thuốc mới để trị một con siêu vi mới : ở mỗi chặng nghiên cứu, sản xuất, đóng chai, phân phối… các nhà sản xuất đều phải vượt qua 1001 thử thách. Thuốc tiêm chống Covid-19 là một sản phẩm tuân thủ luật cung cầu của thị trường ? Nhu cầu về thuốc tiêm chủng chống Covid-19 cho toàn nhân loại ước tính trên dưới 14 tỷ liều. Trên thực tế cho đến cuối 2020, tất cả các nhà máy trên thế giới chỉ có thể sản xuất 3,5 tỷ liều vac-xin. Làm thế nào để trong một thời gian rất ngắn nhân lên gần gấp 4 lần mức cung ứng ? Một số rất ít các nhà sản xuất Trên đài RFI tiếng Pháp, kinh tế gia Nathalie Coutinet giảng dậy tại đại học Paris 13 chuyên nghiên cứu về ngành công nghiệp thuốc trước hết điểm qua vài nét tiêu biểu của một thị trường rất đặc biệt này : « Ngành công nghiệp bào chế vac-xin chiếm 5 % tổng doanh thu thị trường thuốc men toàn cầu, tức là khoảng 5 % trong số 1000 tỷ đô la. Kế tới, đây là một lĩnh vực tập trung trong tay một số rất ít các nhà sản xuất. Trên thế giới hiện có 4 tập đoàn lớn chế tạo vac-xin và số này kiểm soát đến 80 % thị phần. Trong số 4 công ty tên tuổi thống lĩnh toàn cầu, thời gian gần đây Pfizer được nhắc đến nhiều hơn cả. Kế tới là Sanofi, rồi GlaxoSmithKline (GSK) và sau cùng là Merk ». Covid-19 thay đổi cục diện ngành công nghiệp dược phẩm thế giới  Chỉ một con siêu vi cũng đủ để từ gần một năm qua, đại đa số các hoạt động ngoại giao đều thực hiện qua cầu truyền hình. Tệ hơn cả là mùa xuân năm ngoái, hơn một nửa nhân loại bị giam hãm trong nhà : kinh tế bị tê liệt, các nhà máy phải đóng cửa, dây chuyền cung ứng bị gián đoạn... Ngành dịch vụ từ nhà hàng đến khách sạn hay du lịch, đời sống xã hội và văn hóa thể thao đâu đâu cũng bị thu hẹp lại. Ngoại trừ một vài trường hợp riêng lẻ như của Việt Nam hay Đài Loan, Trung Quốc, Âu, Mỹ đồng loạt báo động kinh tế suy sụp ở mức « nguy hiểm nhất từ sau Thế Chiến Thứ Hai ». Trong tình cảnh cấp bách đó ngành dược phẩm lao vào cuộc chạy đua tìm vac-xin mới để phòng ngừa một căn bệnh mới. Trong chưa đầy một năm từ Trung Quốc đến Nga, châu Âu nhưng đứng đầu là Mỹ đã về đến đích : Nga hãnh diện với Sputnik V, Trung Quốc ồ ạt xuất khẩu vac-xin của Sinopharm và SinoVax. Liên doanh Anh và Thụy Điển AstraZeneca giao hàng không kịp cho Liên Hiệp Châu Âu, Mỹ và cả chương trình Covax để cung cấp thuốc cho các nước nghèo. Hoa Kỳ có đến ba hãng chế tạo vac-xin trúng số độc đắc đó là Moderna, Johnson&Johnson và Pfizer. Ông khổng lồ trong ngành dược phẩm này đã hiện diện trên thị trường từ hơn 170 năm nay và hiện có một đội ngũ hơn 80 ngàn nhân viên trên khắp thế giới. Chuyên gia kinh tế Nathalie Coutinet nhắc đến bước đột phá quan trọng nhất trong đối với nền công nghiệp dược phẩm của thế giới trong đại dịch Covid-19 :    « Công nghiệp sản xuất vac-xin trước đây chủ yếu phát triển nhờ công nghệ hóa học, có nghĩa là không sử dụng công nghệ sinh học. Tuy nhiên rất nhiều viện bào chế từ nhiều năm qua đã đẩy mạnh nghiên cứu trong lĩnh vực này đặc biệt là phương pháp dùng vật liệu di truyền ARN thông tin. Công nghệ này chủ yếu được phát triển nhờ các công ty khởi nghiệp với hai mục tiêu ban đầu là tìm ra vac-xin chống ung thư và chống lại siêu vi HIV/AIDS. Lĩnh vực dược phẩm đang trải qua một giai đoạn chuyển biến quan trọng và virus corona chủng mới đã bắt đầu làm thay đổi cục diện của ngành chế tạo vac-xin trong một thời gian dài. Công nghệ ARN đang mở ra nhiều chân trời mới và đang cấu tạo nên một trật tự mới trong ngành dược ». Về phần giáo sư Pierre - Yves Geoffard, trường Cao Đẳng Khoa Học Xã Hội Pháp EHESS, ông lưu ý virus corona đã làm đảo lộn trật tự trên bàn cờ của nền công nghệ dược phẩm vốn trong tay bốn đại gia là Pfizer của Mỹ, Sanofi của Pháp, GSK của Anh, và Merk của Đức :  « Còn hơi sớm để nói tới một cuộc cách mạng, nhưng lĩnh vực sản xuất vac-xin đang có nhiều chuyển biến quan trọng và rất nhanh chóng. Mô hình phát triển trong ngành dược phẩm thay đổi nhanh nhờ đã có nhiều những phát minh mới. Thông thường một hãng lớn mua lại các công ty khởi nghiệp, hoặc mua hẳn bằng sáng chế của các hãng nhỏ. Nhưng lần này đáng chú ý là hãng lớn và lâu đời như Pfizer đã không mua lại bằng sáng chế của BioNTech hay mua lại luôn BioNTech – đây là một hãng của Đức không quá nhỏ nhưng tương đối là khá mới trong ngành. Pfizer chọn cùng với BioNTech bào chế vac-xin chống Covid-19. Có thể nói đây là một hình thức cộng các kiểu mới giữa hãng dược phẩm của Mỹ và của Đức. Thêm một điểm cần lưu ý khác, đó là trong số 4 đại công ty chế tạo vac-xin thống lĩnh thị trường toàn cầu, chỉ có một mình Pfizer tìm ra thuốc chích ngừa chống virus corona. Ba vac-xin khác được ba hãng mà tôi tạm gọi lã những « lính mới » trong ngành làm ra : Moderna, cũng của Mỹ, nhưng là một công ty rất nhỏ. AstraZneca của Anh và Thụy Điển chưa từng bào chế bất kỳ một loại vac-xin nào. Cuối cùng, Johnson&Johnson thì chỉ có một thị phần rất khiêm tốn ». Covid-19, gà để trứng vàng Trong cuộc chạy đua tìm kiếm « thuốc tiên » giải cứu cho nhân loại thoát khỏi nanh vuốt của siêu vi Sars-Co-V-2 đương nhiên những thí sinh về đầu đã giành được những phần thưởng đắt giá nhất. Trong một sớm một chiều Moderna một công ty mới tham gia thị trường dược phẩm thế giới từ 2010 và chưa bao giờ làm ăn có lãi, với hơn 800 nhân viên, trở thành một « đấng cứu tinh » : theo các số liệu công bố tháng 2/2021 một công ty mới chỉ hôm qua còn đứng trong bóng tối thông báo ký hơn 15 tỷ đô la hợp đồng để cung cấp 310 triệu liều vac-xin cho Liên Hiệp Châu Âu cho năm nay và thêm 150 triệu cho năm tới. Mỹ đặt mua 300 triệu liều Nhật Bản là 50 triệu… Virus corona « thổi » cổ phiếu của công ty này lên cao đến hơn 240 % so với cùng thời kỳ năm ngoái. Hành trình của loại vac-xin do liên doanh của Anh và Thụy Điển cộng tác với đại học Oxford không được thanh thản như thuốc sử dụng công nghệ ARN nhưng dự kiến doanh thu của AstraZeneca trong năm 2021 đạt 1,8 tỷ đô la và 2,7 tỷ vào năm tới. Đây là một kỳ công đối với một hãng dược phẩm chưa từng lao vào thị trường chế tạo và sản xuất vac-xin. Về phần Johnson&Johson nhờ chỉ cần một lượt chích và với giá chưa đầy 10 đô la một liều, đơn đặt hàng của tập đoàn có trụ sở tại New Jersey này hiện tại lên tới hơn 1,2 tỷ liều vac-xin.  Sau cùng cặp bài trùng Pfizer BioNTech vừa trúng số độc đắc : doanh thu trong năm nay dự trù đạt 12,5 tỷ đô la mức lãi của tập đoàn ước tính từ « 25 đến 30% » và có thể « là còn cao hơn gấp đôi so với dự phóng ». Là một cây đại thụ trong ngành, cổ phiếu của Pfizer tăng giá 7 % trong năm vừa qua. Riêng với BioNTech, mới chỉ bắt đầu hoạt động từ 2008, thì công nghệ ARN là một sự bất ngờ và là thành công ngoài mong đợi. Do vậy cổ phiếu của BioNTech đã có một bước « đại nhảy vọt ». Marie Ange Saraka Yao trên đài RFI nói đến một thay đổi quan trọng khác virus corona đem lại đó là do đại dịch hoành hành cùng một lúc khắp địa cầu, nhu cầu về vac-xin vượt ngoài khả năng của cả thế giới. Đây là một cơ hội bằng vàng cho một số công ty thuốc của các nền kinh tế đang trỗi dậy : « GAVI là hiệp hội bao gồm nhiều thực thể có liên quan đến thuốc vac-xin như là các cơ quan quốc tế, các viện nghiên cứu, các tổ chức đa quốc gia như WHO, các hãng dược phẩm, … Việc có thêm những hãng mới gia nhập câu lạc bộ các nhà sản xuất vac-xin là một điều đáng mừng vì hiện tại, các nhà sản xuất có thể cung cấp ba tỷ rưỡi liều vac-xin, với đại dịch nhu cầu tăng vọt lên thành 14 tỷ. Làm thế nào đáp ứng nhu cầu tăng đột ngột đó trong một sớm một chiều ? Hiệp hội GAVI khi được thành lập vào năm 2000 làm việc với 5 nhà sản xuất. Giờ đây GAVI hợp tác với 18 viện bào chế mà trong đó có nhiều hãng xuất xứ từ các nền kinh tế đang trỗi dậy. Những hãng chinh phục được thị trường chủ yếu nhờ công nghệ sinh học, họ đem lại một phương pháp làm việc mới và kèm theo đó là những công trình nghiên cứu và phát triển mới. Số này cộng tác với những cái tên tuổi đã quá quen thuộc trong ngành – điển hình là sự cộng tác giữ BioNTech với Pfizer. Ngoài ra chúng ta thấy trong trường hợp của AstraZeneca đây là một sự hợp tác ở cấp toàn cầu. Liên doanh Anh và Thụy Điển này hiện diện tại nhiều nước ở Châu Âu, tại Ấn Độ hay Hàn Quốc. Hơn bao giờ hết chúng ta cần tất cả các quốc gia trên thế giới chung tay để đáp ứng nhu cầu cùng một lúc cho cả thế giới ».  Ấn Độ nhà thuốc của thế giới Ấn Độ từ nhiều năm qua đã trở thành nhà sản xuất thuốc và vac-xin lớn nhất thế giới. Đây cũng là nơi mà hầu hết các tập đoàn dược phẩm đều đặt cơ sở sản xuất. Covid-19 xác định lại điều đó. Có điều ngay cả đến nhà cung cấp này cũng đã bị bất ngờ vì virus corona chủng mới như thông tín viên Sébastien Farcis từ New Delhi tường thuật :    « Andar Poonawalla hiện là một trong những nhân vật quan trọng nhất tại Ấn Độ. Ông là tổng giám đốc tập đoàn dược phẩm Serum Institute of India, công ty sản xuất vac-xin lớn nhất trên thế giới và là nguồn cung cấp thuốc của AstraZeneca cho toàn cầu. Cách nay vài tháng khi mà thuốc của liên doanh Anh và Thụy Điển còn chưa được phép sử dụng, giám đốc công ty đã bắt đầu ngừng sản xuất các loại vac-xin khác để dành hết mọi ưu tiên cho thuốc của AstraZeneca. Ông nhấn mạnh, quyết định này có được nhờ tập đoàn không lệ thuộc vào các ngân hàng hay cổ đông mà hoàn toàn độc lập về mặt tài chính. Trước đại dịch Covid-19, mỗi năm Ấn Độ sản xuất hai tỷ rưỡi liều vac-xin, tương đương với hơn 50 % nhu cầu tiêu thụ trên thế giới. Năng suất của Ấn Độ trong năm nay tiếp tục tăng thêm hơn 40 % so với bình thường. Hiện tại, Ấn Độ là quốc gia sản xuất vac-xin chống Covid-19 lớn thứ nhì - chỉ thua có Mỹ. Sắp tới đây Ấn Độ nhận thêm hợp đồng sản xuất vac-xin Sputnik V của Nga và Janssen của hãng Mỹ Johnson&Johnson. Milan Patel chủ tịch hiệp hội các tập đoàn công nghiệp sản xuất vac-xin Ấn Độ nêu bật những lợi thế của quốc gia Nam Á này : trên toàn quốc có 1.500 nhà máy được chứng nhận đáp ứng các tiêu chuẩn của Tổ Chức Y Tế Thế Giới. Ở ngoài lãnh thổ Mỹ, Ấn Độ là nơi thứ nhì Cơ Quan Y Tế Hoa Kỳ tín nhiệm nhất. Theo ông Patel, điều đó cho thấy rõ uy tín của Ấn Độ với cộng đồng quốc tế về khâu sản xuất vac-xin. Ấn Độ xuất khẩu 64 triệu liều thuốc tiêm chống Covid-19 cho thế giới, trong đó 18 triệu nhằm phục vụ chương trình CoVax cung cấp cho các nước nghèo. Trong bối cảnh dịch bệnh bùng phát trở lại với đà quá nhanh, New Delhi đã cấm xuất khẩu vac-xin, dành ưu tiên cho thị trường nội địa. Dù vậy giới trong ngành cho biết với nhịp độ tiêm chủng 4 triệu người mỗi ngày, từ nay đến giữa tháng 6/2021 Ấn Độ sẽ có thể cung cấp thuốc trở lại cho thế giới. AstraZeneca cảnh cáo New Delhi về nghĩa vụ xuất khẩu vac-xin như tập đoàn Serum Institute of India đã cam kết ».

it is indeed a known fact that entire world have been ravaged with a severe viral infectious disease that has claimed millions of lives. Take a Listen to this insightful and informative "HEALTH & WELLNESS" segment with Dr. Bilikis - Medical Analytics Director for US Medical Affairs at GlaxoSmithKline (GSK). --- Send in a voice message: https://anchor.fm/afolarin-ani/message

Part of our apprentice panel podcasts, Jamilah Simpson our apprentice panel host interviews member, Nikki Greaves.   Nikki Greaves, 20, is currently completing her level 5 laboratory science apprenticeship with GlaxoSmithKline (GSK).   Transcript Jamilah Simpson: Hi, I'm Jamilah Simpson the Multiverse Community Programs and Networks Associate. I joined Multiverse early last year after completing my digital marketing qualification as an apprentice at Google. I'm also an apprentice panel member and your host for this podcast. Today we're joined by Nikki. Nikki did you quickly want to intro yourself before we get started Nikki Greaves: Hi, I'm Nikki a laboratory science apprentice for GSK currently in my third year now. Jamilah Simpson: Thank you, Nikki, we're so glad to have you here today. So, I've got a few questions for you. Starting with, as we both chose the apprenticeship route, I think we can both agree that there are so many benefits to them. What drew you into your apprenticeship? Nikki Greaves: So it's weird actually, I knew in sixth form that I wanted to go into a sciencey kind of lab-based career, and I was actually really set on doing a Biomed kind of degree at uni. My school was very like forward at pushing us down the uni kind of route, and it was only one day when I was looking at the government website that I actually stumbled upon the GSK apprenticeship,  and I was actually really intrigued. Because probably like quite a few other people I just assumed that apprenticeships were like carpentry and plumbing. Obviously, that sounds really bad, but I really didn't have much of a clue of what apprenticeships actually were. So when I saw this advertisement basically being like you can have a degree and learn hands-on I was pretty much like wow, this is actually exactly what I want. Because obviously the whole sitting in lectures, and that's just not how I learn and I was actually really worried about that aspect of uni. So actually, getting a hands-on was so much better for me, so I applied immediately. Jamilah Simpson: I had the exact same reaction because I didn't have a lot of information about apprenticeships when I was at college either. When I found out that there's so many different industries that you can go in to, I got really excited. I actually found my apprenticeship through my mum, so similar to you, my school wasn't helpful at all. Nikki Greaves: I honestly didn't even know they existed like at all. Jamilah Simpson: So Nikki your apprenticeship sounds really, really interesting and I'd love to know more about what you do day-to-day. Nikki Greaves: So, the usual day for me consists of helping my team set up and run studies. Where we basically look at how different compounds work. So how they work in the body if they're going to the right places and doing what we want them to do basically. A particularly interesting project that I've been involved in, was working on an HIV project where we looked at the potential for a treatment to take place twice a year rather than the current treatment regime, which is administered monthly. Jamilah Simpson: Wow sounds like pretty important stuff. So as you know we've all been going through a really tough time over the past year as a nation. Being a laboratory scientist, have you had an opportunity to support with COVID- 19? Nikki Greaves: Unfortunately not. I would have absolutely loved to be involved, but my team and I have just had a lot of work that's ongoing. Like I have been in work as a key worker, but it hasn't been COVID involved. Although I have actually signed up to be a volunteer for the mass vaccinating and actually GSK like alongside the NHS organised that for some of the employees. So I'm doing that. Jamilah Simpson: That's amazing. You mentioned that you're a key worker does that mean that you still go into your place of work? Nikki Greaves: Yeah, so pretty much throughout the lockdown we were going in on a like shift kind of pattern. So that obviously there's like a limited amount of people on-site, but yeah pretty much just working our way through it. Because obviously a lab base, I can't exactly work from home very much. As much as I try and say my coursework, I could get on with my coursework. But yeah I know we've just been doing shifts really. Jamilah Simpson: Well I can imagine that must be really difficult to go through Nikki Greaves: it's actually. I feel like it gives regularity to the days. It is a bit difficult to like, make a routine because sometimes you're called in last minute, or sometimes then you're not needed. So, that's probably the hardest bit, but other than that it's still nice to be able to talk to people other than my housemates, as much as I love them. Jamilah Simpson: Yeah, I really struggled to maintain that routine when I was working from home and I've recently started coming back into the office a few days a week. It's just nice to have that commute. It's something that I never thought that I'd miss having that commute in the morning and actually getting on a train. I really missed that during the first lockdown. So now I'm getting back into it it's just nice to have that distinction between work. So on to our next question. What would you like to do next after you've finished your apprenticeship? Nikki Greaves: So, I'm currently doing a level 5 apprenticeship. So I'm in my third year now, so hopefully, fingers crossed if all goes well, in August time I'll get my bioscience foundation degree. Then I'm hoping to basically stay on at GSK for another year and a bit, to get a level 6 apprenticeship, and get my full bachelor's degree, so hopefully that. As for after that I'm just hoping I can get a full-time job at GSK, and maybe explore different departments. Because I'm still not really sure what I want to particularly do. I think the science industry is so like varied, and so wide. I think there's just so much to explore still. So we'll have to see. Jamilah Simpson: I think it's amazing that you're thinking about going on to a level 6. I didn't even know that existed until a few weeks ago. The fact that you've also like kind of got a plan in place I really respect that. I'm not much of a planner I just like take things as it comes. I think I'm going to start definitely thinking about like the 5-year plan and the 10-year plan going forward. Nikki Greaves: I feel like I need to be more that. I'm too like plan it all, plan it all, I really need to kind of take things on the chin a bit more. Jamilah Simpson: We can help each other out we can balance. So we know that you're part of the apprentice panel, along with myself. Why did you decide to join the panel in the first place? Nikki Greaves: Well, I just think it's a great opportunity. I think being able to work with people, who are like-minded, who also have a passion for apprenticeships. I just think that was a great opportunity and it also gives me an opportunity to give maybe apprentices that don't have a voice, like a platform for them to speak out, and give their opinion. So, I just thought it was a great opportunity to have. Jamilah Simpson: It's quite an empowering experience, isn't it? Something that we're working on in the apprentice panel, is the best practice guidance for apprenticeships. I believe that you're in the induction process. Nikki, can you tell me why that part is so important? Nikki Greaves: I just feel like the induction of anything is just important. I mean like it's the part that sets you up. It's the part where you get told what to expect, and the experiences that you'll get, and what you'll learn. So I just really feel like a great induction can have such an impact, and it will really set you up for the rest of your apprenticeship. Jamilah Simpson: Yeah, definitely, I agree. Out of curiosity what was your induction process like? Nikki Greaves: So, I went on-site, like a month before, and it didn't go very well. I actually was so nervous the night before that I didn't sleep very well. Then in the morning, because I lived quite far away, and I actually commuted in the morning. It was like an hour drive, so I had barely eaten, like a banana, so and then I had a really long journey. So I was absolutely knackered, and I actually fainted. Jamilah Simpson: Oh my god, that's awful. Nikki Greaves: As it was it was, actually quite good. On my first day, because it kind of was an ice breaker. I was like the girl that fainted if you remember me. So, it kind of worked out in the end. As embarrassing as it was. Jamilah Simpson: Oh wow, that sounds very intense. By being on the apprentice panel what do you want to achieve? Nikki Greaves: Well, like I said, just to have a platform for apprentices to raise their opinions. Also, to just help with improving the overall apprentice experience. I feel like there's such a range of different experiences, and I feel like making that all like merge, and all actually go together, so that everyone has similar experiences. I think that all that's a really good thing to work towards. Jamilah Simpson: Definitely. I 100% agree. Finally, you briefly mentioned the fact that you didn't really have support from school when you were looking for your apprenticeship, and you were quite surprised when you found out the opportunity that you're in now. Have you got any advice for people thinking about doing an apprenticeship? Nikki Greaves: Yeah, so I would just say explore apprenticeships online, on government websites, there's just so many actually available that people don't realise. So I just say do your research. It's a really great alternative to university, you get to network with so many professionals in your field. I just feel like it opens so many doors. So I just say go for it, research it, apply. Jamilah Simpson: Yeah, I think we both have, like biased opinions, because we both, like you're on an apprenticeship at the moment, and I've completed mine last year. So we only have like good things to say about apprenticeships. But I definitely agree with your point about research and making sure that you know what you're getting yourself into before you actually commit. So, thank you. That's all we have time for in today's episode. I want to say a huge thank you to our guest Nikki for taking the time to tell us about your apprenticeship experience and being so open and honest with me today. Thanks for listening, and look out for our next episode. Bye.

Dr. Tania Gonzalez-Rivera, MD, BENLYSTA Global Medical Affairs Lead at GlaxoSmithKline (GSK) discusses the recent FDA approval of BENLYSTA (Belimumab) the first and only approved biologic treatment for both lupus and adult patients with active lupus nephritis who are receiving standard therapy. This approval builds on 10 years of clinical evidence. Tania C. González-Rivera, MD, BENLYSTA Global Medical Affairs Lead at GlaxoSmithKline (GSK), has a deep breadth of experience in Medical Affairs spanning a variety of therapeutic areas. As a board-certified rheumatologist with clinical expertise in systemic lupus erythematosus (SLE) and other complex autoimmune diseases, she also has extensive knowledge regarding clinical trials and a background in translational research for SLE and lupus nephritis (LN). Dr. González-Rivera earned her Doctor in Medicine and completed her Residency in Internal Medicine at the University of Puerto Rico School of Medicine, and completed her Rheumatology Fellowship at the University of Michigan.

Top 5 Undervalued High Dividend Covid-19 Vaccine Stocks To Buy Now

Are the vaccines that will be released to the public safe? Have they been tested with diversity in mind? In order to make the best decisions for your health, it's best to know and understand the process of how drugs and vaccines are developed. In this episode, I bring in Dr. Marquita Qualls-- a chemist with a background in drug development. Dr. Qualls professional career began at GlaxoSmithKline (GSK), one of the leading pharmaceutical companies in the world. During nearly a decade at GSK, she held roles of increased global responsibility spanning drug development, technology evaluation, program management, strategy, and people development. Hopefully, this episode will help you make better-informed decisions regarding COVID, and the vaccines during these times of uncertainty. Episode Highlights: About Dr. Marquita Qualls How she got her degree and how long it took Dr Q's obstacles in getting her PhD as the only black woman and how she dealt with it Her experience with GlaxoSmithKline The process of drug development Inclusivity and diversity in clinical trials Covid from those in the perspective of one in the pharmaceutical industry Her shifting careers and gaining an entrepreneurial mindset Going for your dreams About our Guest: Dr. Marquita M. Qualls has over 20 years of leadership experience in consulting, coaching, and motivating people who want to produce order out of their chaos. Though a scientist by training, she commands a masterful understanding of the interpersonal skills needed to thrive in today’s fast-paced and competitive business environment. Marquita made history by becoming the first female African-American to receive her Ph.D in chemistry from Purdue University. Connect with Dr. Marquita Qualls:  Entropia Consulting Dr. Marquita Qualls on Twitter Dr. Marquita Qualls on LinkedIn Dr. Marquita Qualls on Facebook Dr. Marquita Qualls on Instagram — Did you enjoy today’s episode? Please subscribe and leave a review. If you have questions, comments, or possible show topics, email runningischeaperthantherapyolb@gmail.com. To subscribe and review use one links of links  below  Apple Spotify Google  Get a copy of the book  Running Is Cheaper Than Therapy: A Journey Back to Wholeness

this week we reviewed both our portfolios in relation to its Q3 performance. We started the show with the news of the week EMF asks European DGI about his opinion of Unilever's HQ move to the UK. eDGI shares his historical perspective for this move and why it makes sense to choose the UK. He does bring up the point though about its dividend reliability if Unilever starts to use the British Pound as their base currency. Will it mean that Euro investors will be exposed to additional currency risk? https://www.thisismoney.co.uk/money/m... EMF also shares the recent news about Shell. Shell is planning to cut up to 9000 jobs and we talk about what it might mean for the company. https://edition.cnn.com/2020/09/30/bu... EDGI shares his thoughts about Bayer. Bayer just announced an adjusted performance outlook. It also gave a heads-up about upcoming impairment charges in its agriculture business. What to do with Bayer, that's really the question. https://www.investor.bayer.com/en/nc/... Last but not least, EMF and eDGI also share their support for Beurswolf's S&P500 major league. They find it a very interesting and competitive contest. They're recommending everyone to join the contest via Twitter. https://beurswolf.com/2020/09/28/sp50... Main Topic: The main topic was about reviewing their portfolios and how it performed in Q3 2020. eDGI's income from dividend was still growing strongly while his absolute portfolio value stayed flat. This was mainly due to a drag down in his Oil stocks and net new monthly contributions. EMF mentioned that Q3 was all about cleaning up his portfolio. He sold 15 positions and started to put strength back in his portfolio by focusing on high quality positions, Also EMF enjoyed a strong growth in his year-over-year dividend income. Listeners Questions: This week we answered the below questions: Andrew - I have been assessing Glaxosmithkline (GSK) and have opened a small position. What do you think of this as a good pharma purchase. Danny - Thoughts on how Trump catching Covid might affect the presidential race along with the stock market ? Centrino - $XOM : buy now for its high divi (oil is still there for many years) ? Or run away, because future is electric and gaz? Letuscompound - Thoughts on our favorite laggard Shell? 30 min rant from edgi please :) Phil - Is taxation a reason for you not to invest in something Gerry Farrel - Any thoughts on Neste Oyj? Neste Oyj is a Finland-based company engaged in the refining and marketing of petroleum and petroleum products Last but not least, we both shared our stock pick of the week. While you're at it, don't forget to hit the Subscribe and Like button

As Sanofi and GSK secure the deal to supply up to 60 million potential vaccines to the UK government, we are looking at the pharma stocks involved in the race. IGTV’s Victoria Scholar is joined by IG’s Josh Warner, who talks us through some of the companies, including Pfizer, AstraZeneca, and Moderna. Josh explains why governments are eagerly buying stock in advance, and reminds that there are no vaccines from previous versions of coronavirus. The two discuss the opportunities for investors in the current uncertain environment. Follow us on Twitter @IGTV Fundamentals and charts: GlaxoSmithKline (GSK) Sanofi AstraZeneca Moderna Pfizer (All Sessions) BioTech  

Adam Hoy is VP, Head of Worldwide Real Estate & Facilities at GlaxoSmithKline (GSK) having previously held global roles at Nestle and Unilever.   In this podcast, part of our 'Leadership' series and recorded prior to the coronavirus pandemic, Adam discuses assembling global teams, managing up as well as managing down, sustainability, productivity and lifelong learning.

Ira Pastor, ideaXme life sciences ambassador and founder of Bioquark, interviews, Naveen Jain, M.B.A, BS, Founder and CEO at Viome as well as founder of several companies including Moon Express, Viome, Bluedot, TalentWise, Intelius and InfoSpace.   Ira Pastor comments: On this ideaXme episode, we are going to head back towards the theme of the human micro-biome, which represents the estimated 100 trillion aggregate of all microbiota (bacteria, fungi, protists, viruses, etc. ) that reside on, within, or symbiogenically as part of the human body, and their downstream effects on human health, wellness, and longevity. Naveen Jain Believes in Using Food as Medicine: Naveen Jain is a philanthropist, technology pioneer and entrepreneur, driven to solve global grand challenges through innovation. He is the founder of several successful companies including Moon Express, Bluedot, TalentWise, Intelius and InfoSpace, and Viome, which is the topic of today's episode. Viome is focused on disrupting healthcare with the goal of “making illness elective”, by identifying microbial bio-markers that are predictive of chronic diseases, and adjusting the microbial imbalance through personalized nutrition, in essence making illness truly a matter of choice, and not a matter of bad luck, using foods as a medicine. Personalized Healthcare: Through Biotech and AI Mr. Jain is also director of the board at the Singularity University where he is focused on educating and inspiring leaders to address humanity’s grand challenges through innovative technologies. Mr. Jain is a director of the board at the XPRIZE Foundation where he is focused on using incentive prizes to find solutions to many of the societal challenges and recently launched a million-dollar Women Safety XPRIZE to empower women around the world. He has been awarded numerous honors for his entrepreneurial successes including, but not limited to, the “Ernst & Young Entrepreneur of the Year”, the “Albert Einstein Technology Medal” for pioneers in technology, the “Ellis Island Medal of Honor”, and the "Most Creative Person” award by Fast Company. In addition to Viome, on the life sciences/biotech front, Mr. Jain is in the process of setting up an incentive prize challenge to develop “Digital Doctor” (AI based expert system) to improve access to primary care physicians around the world. He is also exploring ways to develop a neurometric system to create better learners and to develop neuroscience based multi-sensory video games that are effective and additive to teach students skills like math, science and history. Mr. Jain is also a strong believer that we should be doing a lot more on the synthetic biology front, creating living bio-factories to reduce global shortages of food, and use microbes to help with cleaning water and generating energy from plentiful resources like ocean water. On this ideaXme episode, we will hear from Mr. Jain about: His background, how he developed an interest in engineering, and about his info-tech business success in the "pre-Viome" era. Why he made the jump into the risky biotech industry. Viome's business model, products, and services. Viome's collaboration with the Mayo Clinic on AI-driven personalized nutritional strategies to help understand sleep and obesity. Viome's collaboration with GlaxoSmithKline (GSK) to develop vaccine-based therapies to help prevent and treat chronic diseases. The state of the biotechnology financing world. His Moon Express initiatives. This interview is in American English Credits: Ira Pastor interview video, text, and audio. Follow Ira Pastor on Twitter: @IraSamuelPastor If you liked this interview, read our interview with Dr. Michael Lustgarten! Follow ideaXme on Twitter: @ideaxm On Instagram: @ideaxme Find ideaXme across the internet including on iTunes, SoundCloud, Radio Public, TuneIn Radio, I Heart Radio, Google Podcasts, Spotify and more. ideaXme is a global podcast, creator series and mentor programme. Our mission: Move the human story forward!™ ideaXme Ltd.

A organização humanitária internacional Médicos Sem Fronteiras (MSF) lançou, no dia 23 de abril, uma campanha global – “A dose justa” – para pedir às farmacêuticas GlaxoSmithKline (GSK) e Pfizer que reduzam o preço da vacina pneumocócica em países em desenvolvimento para US$5 por criança, para que mais crianças possam ser protegidas desse assassino da infância, e que revelem o que é atualmente cobrado dos países pela vacina. Uma parceria da Agência com Médicos sem Fronteiras.

This week's Alpha Trader podcast features hosts Aaron Task and Stephen Alpher talking COVID-19 treatments and vaccinations with Adam Feuerstein of Stat News. Much of the treatment talk has been about Gilead's (GILD) remdesivir, and Feuerstein - who has been at the center of much of the reporting - takes us through those ups and downs. First, there was anecdotal evidence on April 16 out of Chicago which suggested the drug as being almost miraculously effective - the news set off a nice move higher in Gilead (more on that later), and a furious rally in the broader markets. Next, there was a "leak" one week later out of the WHO that a trial of the drug in China was a flop - the news took the starch out of a sizable rally in stocks that day. Finally, one day after that, there was a report that results from U.S. government's all-important trial of remdesivir were going to hit in mid-May, and chatter that those results might show the drug as being effective. Feuerstein does find it somewhat curious that Gilead's stock rises and falls with the news about remdesivir given that the company has more or less said it will give the drug away (after recouping costs). The halo effect? Possibly, but Gilead has added nearly $20B in market cap over the past three months. In any case, Gilead reports Q1 earnings after the close on Thursday - it might make for a good time to report on remdesivir results from one of the company trials (not from the above-mentioned U.S. government trial). Feuerstein reminds that remdesivir is only a treatment for COVID-19, and even in a best-case scenario will be effective in curing only certain patients. What the world ultimately needs is a vaccine, and there are currently five in clinical development, i.e. being tested on people. There are a number of others in pre-clinical development as well. One of the more advanced at this time is Moderna (MRNA), and that stock has nearly tripled over the past couple of months. Major pharmaceutical players (and experienced vaccine hands) Johnson & Johnson (JNJ), Pfizer (PFE), GlaxoSmithKline (GSK), and Sanofi (SNY) are also hard at work. Vaccines, however, take time to develop. If all goes right, says Feuerstein, we're looking at 12-18 months. Any stumbles, and it would take even longer.

The Big Ones It is the sort of line to awaken the curiosity in an annual report: “Cash payments to acquire equity investments amounted to £258m [$314m] (2018 – £309m), primarily relating to Lyell Immunopharma.” Thus, the accountants revealed UK-listed drugs maker GlaxoSmithKline (GSK) had invested a sizeable amount in US-based cancer treatment developer Lyell Immunopharma, … Continue reading "06 April 2020 – Lyell Immunopharma Gains $493m Investment from GlaxoSmithKline"

Jim Harris is a one of North America

If you are new to our TwinPetesInvesting podcast (https://soundcloud.com/user-479955511) welcome. If you are back for more thank you. Please subscribe to our AudioBoom, SoundCloud (https://soundcloud.com/user-479955511) & iTunes (https://podcasts.apple.com/gb/podcast/conkers-corner/id1384481834?mt=2) channels so as not to miss out on future episodes, that could enable you to learn more rewarding investing, trading insights and strategies.  Please share this podcast with others that you know will find it of interest. In Part 1 of this thirteenth TwinPetesInvesting podcast the topics and shares discussed include: The winning AI tech stock that is up 195% ytd; The importance of Artificial Intelligence in relation to drug discovery, pharma, biotech, healthcare & clinical trials; Astra Zeneca AZN; GlaxoSmithKline GSK; Biogen $BIIB; Ixico IXI; Clinigen CLIN; Neuroscience; Digital Imaging; Data Analytics; BigData; Parkinson's Disease; Dementia; Alzheimer; Oncology; Healthcare; Alliance Pharma APH; Tristel TSTL; Hotel Chocolat HOTC; Woodford Funds; Unicorns; Woodford Patient Capital Trust WPCT; Rainbow stocks; High PEs; Book: "How to make Money in stocks" Metro Bank MTRO; Technical Analysis; Entertainment One ETO; Patience; Income dividend plays; Dividends; Psychology; Investing & more. The Twin Petes Investing podcast will be linked to and written about on the Conkers3 website  (https://www.conkers3.com/news-research-articles/) and also on the WheelieDealer website (http://wheeliedealer.weebly.com/)

The SecureWorld Sessions is a new cybersecurity podcast that gives you access to people and ideas that can impact your cybersecurity career and help you secure your organization. The featured interview in this episode is with Dawn-Marie Hutchinson, CISO of Pharmaceuticals and R&D at GlaxoSmithKline (GSK). The interview, conducted at a SecureWorld conference following Dawn-Marie's keynote, covers several security topics. How do you define and explain identity centric security? What does it look like when security enables the business as an organization goes through digital transformation? Where are many organizations failing in data governance? And much more. The episode also features the “Trend Micro Top 3,” where we unpack three top findings from Trend Micro research into IoT exploit monetization based on what hackers are doing in IoT hacker forums on the cybercrime underground.  Links related to the episode: Trend Micro research: Uncovering IoT Threats in the Cybercrime Underground (https://www.trendmicro.com/vinfo/us/security/news/cybercrime-and-digital-threats/the-internet-of-things-in-the-cybercrime-underground) SecureWorld conference map & calendar: https://www.secureworldexpo.com/events Cybersecurity insights from our security news website: https://www.secureworldexpo.com/industry-news

In this special episode, Curtis interviews two GlaxoSmithKline (GSK) spokesmen about Meningococcal disease, a rare but aggressive bacterial infection that can be fatal or cause life-long disabilities. It is preventable and there is a vaccine for five serogroups of the disease. Dr. Leonard Friedland is a husband, a father to two adult children, a pediatrician, and VP at GSK who has worked in the field of infectious disease vaccination since 2003. In addition to learning about his great work with vaccines, we also get marriage and parenting tips from Dr. Friedland.Nick Springer is a gold medal Paralympian in wheelchair rugby and a meningitis survivor whom, at the age of 14, contracted meningitis, fought for his life for 2 months, while enduring 19 surgeries and four amputations. As Nick tells his story, his optimism for life and for living it to it's fullest shines through. He explains how this disease completely caught him and his family off guard, but how it has allowed him to now be a spokesman for HOPE. Nick shares amazing stories and tips about parenting and positive mental attitude that he observed watching his parents and sister help him recover.For full notes and more information, visit http://www.dmdlifestyle.com/dmd12

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Genentech, Lodo Therapeutics, Eli Lilly, Pfizer, Roche, Sanofi, Johnson & Johnson, Merck & Co. MSD, Novartis, Abbvie, Gilead Sciences, GlaxoSmithKline (GSK), Amgen, Takeda, ShireNuove terapie: LentiGlobin™, Bevacizumab, DaratumumabPatologie: HIV, HPV, degenerazioni retiniche, Beta-talassemia, Mieloma multiploLavoro: Medical Science Liaison, Senior Clinical Research Associate Sponsor dedicato Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

GlaxoSmithKline (GSK) is a company that divides opinion and therefore an ideal candidate for the IC's Bull vs Bear series. In this episode, Simon Gergel from the Merchants Trust argues the bull case against the ICs pharma specialist (and GSK sceptic), Megan Boxall. See acast.com/privacy for privacy and opt-out information.

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: Genentech, Lodo Therapeutics, Eli Lilly, Pfizer, Roche, Sanofi, Johnson & Johnson, Merck & Co. MSD, Novartis, Abbvie, Gilead Sciences, GlaxoSmithKline (GSK), Amgen, Takeda, ShireNuove terapie: LentiGlobin™, Bevacizumab, DaratumumabPatologie: HIV, HPV, degenerazioni retiniche, Beta-talassemia, Mieloma multiploLavoro: Medical Science Liaison, Senior Clinical Research Associate Sponsor dedicato Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

Welcome to Episode #13 of the Value Investor Podcast Every week, Zacks value stock strategist and the Editor of Zacks Value Investor portfolio service, Tracey Ryniec, talks about all things happening in the value stock universe, including her top stock picks. This week, Tracey discusses how value investors need to look for buying opportunities. Value investors buy in industries and sectors everyone else is scared of. Fear is the value investor’s friend. Right now, one of the most fearful parts of the global economy is in Great Britain. The Brexit vote is continuing to have investment ramifications as questions swirl about whether it will be a difficult separation or not. The British pound just suffered one of the top 40 worst 4-day periods in its history, as it fell nearly 5%. It is at 1985 lows. A value investor might ask: are British stocks being hit just as badly? And if so, are there some buying opportunities there? Tracey looks at the ways you can get into the game including through buying British companies that are trading on the US stock exchanges as well as through buying country-specific ETFs. The ETFs give you more diversified exposure. Are British Stocks on Sale? 1. GlaxoSmithKline (GSK) has a forward P/E of 16.7. It also pays a dividend yielding 4.6%. 2. AstraZeneca (AZN) is trading with a forward P/E of 15.5. Shareholders are rewarded with dividends yielding 4.3%. 3. British American Tobacco (BTI) isn’t very cheap. It has a forward P/E of 19. Tracey is also keeping a couple of stocks on her “watch” list. Which ones does she think have potential? What About Country ETFs? 1. iShares United Kingdom ETF (EWU): specializes in mid-and-large cap companies. Only down 3% on the year. 2. iShares United Kingdom ETF (EWUS): focuses on 240 small cap companies. It is down 12% year-to-date. Tracey believes there is a buying opportunity in one of these. Which one does she like? Check out this week’s podcast to find out what values may lurk in the British Isles. ISHARES MSCI UNITED KINGDOM ETF: https://www.zacks.com/funds/etf/EWU/profile?cid=cs-soundcloud-ft-podISHARES MSCI UK SMALL CAP INDEX FUND: https://www.zacks.com/funds/etf/EWUS/profile?cid=cs-soundcloud-ft-pod Glaxosmithkline:https://www.zacks.com/stock/quote/GSK?cid=cs-soundcloud-ft-pod Astrazeneca Plc: https://www.zacks.com/stock/quote/AZN?cid=cs-soundcloud-ft-pod British Am Tob: https://www.zacks.com/stock/quote/BTI?cid=cs-soundcloud-ft-pod Follow us on StockTwits: stocktwits.com/ZacksResearch Follow us on Twitter: twitter.com/ZacksResearch Like us on Facebook: www.facebook.com/ZacksInvestmentResearch

Dr. Marquita M. Qualls has over 25 years of leadership experience in consulting, coaching, and motivating people who want to produce order out of their chaos. Though a scientist by training, she commands a masterful understanding of the human aspects needed to thrive in today’s fast-paced and competitive business environment. She founded Entropia Consulting, a small management consulting firm that focuses on helping individuals become more productive and effective leaders. Listen on iTunes, Stitcher Radio or TuneIn In this episode, I asked Dr. Qualls several questions, including: What was your dream growing up? What inspired you to pursue a degree in Chemistry? What are some of the biggest lessons you learned about yourself during your years with Glaxo? Tell us about your transition from Glaxo to starting your own consulting business? What is the exact problem your clients are having and how are you able to help provide a solution through your coaching services? Share one of your road blocks that caused you to have to take a major detour. What happened and how did you overcome it and get back on track?  How do you learn to love doing hard work you don't want to do? Why is learning a super power? What does successful leadership look like? What can we look forward to with you? Are there any big dreams and goals on your vision board for the next 5-10 years and beyond that you'd care to share with us? Links and resources mentioned: Marquita Qualls on Entropia Consuting Marquita Qualls on Twitter Marquita Qualls on LinkedIn Marquita's Fav Resources: Schedulista Marquita's Fav Book: Oh, The Places You'll Go!   Marquita M. Quall's Bio Marquita M. Qualls, Ph.D. has over 25 years of leadership experience in consulting, coaching, and motivating people who want to produce order out of their chaos. Dr. Qualls possesses the rare combination of strong technical ability and impressive soft skills. Though a scientist by training, she commands a masterful understanding of the human aspects needed to thrives in today’s fast-paced and competitive business environment. Her technical side drives an ability to gather perspectives and analyze feedback, while at the same time connecting with clients and guiding them towards achieving results. This has enabled her to function and make seamless transitions between the scientific and non-technical worlds. She has a gift for listening to what's not being said and asks the probing questions to help you arrive at a solution. Her style is often described by her clients as energetic, engaging, and empowering. She understands what it takes to be an extraordinary leader. She is a former National President of a professional technical organization and was a member of the team that created the Leadership Development System® for the American Chemical Society, the world's largest scientific society. She has also served on the editorial advisory board of Chemical & Engineering News, The Chemical Science Roundtable of the National Academies, and an Entrepreneur in Residence with Innovate Mississippi . Dr. Qualls has consulted with teams and coached professionals within governmental, educational, corporate, and nonprofit sectors including the Department of Homeland Security, GlaxoSmithKline, Novartis, Jackson State University, P&G, Purdue University, The Dow Chemical Company, and American Chemical Society, Association of Women in Science, NOBCChE and SACNAS. Dr. Qualls’ professional career was rooted at GlaxoSmithKline (GSK), one of the leading pharmaceutical companies in the world. During nearly a decade at GSK, she held roles of increased global responsibility spanning drug development, technology evaluation, program management, strategy development, and people development. She founded Entropia Consulting, a small management consulting firm that focuses on helping individuals become more productive and effective leade...

Today's buzz: Bribery and corruption are alive and well. The global economy continues to bring great opportunities and great risks. Wherever you do business, do you have measures in place to detect and thwart clever bribery and corruption fraud schemes, especially those cooked-up by trusted staff or consultants? Perhaps technology can help. The experts speak. Thomas Fox, attorney, independent consultant: “GlaxoSmithKline (GSK) in China will be a complete game-changer in bribery and corruption enforcement across the globe.” Vincent Walden, Ernst & Young: “'Parkinson's Law: Work expands so as to fill the time available for its completion.' Why: Think about the ‘new' types of work we will do, given the game-changing performance enhancements of Big Data.” Melissa Lea, SAP: “Two things are infinite: the universe and human stupidity; and I'm not sure about the universe” (Albert Einstein). Join us for Compliance: Focus on Anti-Bribery/Anti-Corruption – Part 2.

Today's buzz: Bribery and corruption are alive and well. The global economy continues to bring great opportunities and great risks. Wherever you do business, do you have measures in place to detect and thwart clever bribery and corruption fraud schemes, especially those cooked-up by trusted staff or consultants? Perhaps technology can help. The experts speak. Thomas Fox, attorney, independent consultant: “GlaxoSmithKline (GSK) in China will be a complete game-changer in bribery and corruption enforcement across the globe.” Vincent Walden, Ernst & Young: “'Parkinson's Law: Work expands so as to fill the time available for its completion.' Why: Think about the ‘new' types of work we will do, given the game-changing performance enhancements of Big Data.” Melissa Lea, SAP: “Two things are infinite: the universe and human stupidity; and I'm not sure about the universe” (Albert Einstein). Join us for Compliance: Focus on Anti-Bribery/Anti-Corruption – Part 2.

Listen NowRecently the French government fined Sanofi $53 million for what it called a smear campaign against a competitor drug manufacturer.   Ranbaxy was fined $500 million, in part, for making false statements to the FDA.   Last year the pharamaceutical industry in sum paid out $5.5 billion to resolve fraudulent marketing practices.  These included $3 billion in fines against GlaxoSmithKline (GSK) and $762 million against Amgen.   When these settlements were reached eight of the top 10 global pharmaceutical companies were under "corporate integrity agreements"  (that require companies to report compliance activities via an independent monitor for five years).   With governments recouping only a portion of drug company profits via these marketing practices many say pharma simply views the fines as a cost of doing business.  (The day the GSK fine was announced, the largest of its kind in history, GSK's stock price actually closed up).During this 23-minute interview Dr. Fugh-Berman discusses the types and pervasiveness of pharmaceutical marketing abuses, the public health consequences thereof, the adequacy of corporate integrity agreements and other efforts that promise to curb abuse (e.g., the Physician Payment Sunshine Act), her views regarding direct to consumer advertising, Pharmed Out's efforts to better educate (or insulate) physicians, patients and other consumers from marketing manipulation.    Dr. Adriane Fugh-Berman is an Associate Professor in the Department of Pharmacology and Physiology and in the Department of Family Medicine at Georgetown.   She is also Director of PharmedOut a research and education project that promites rational prescribing and exposes the effect of pharmaceutical marketing on prescribing practices.  Previously, Dr. Fugh-Berman was a medical officer in the Contraception and Reproductive Health Branch of the National Institute for Child Health and Human Development at the NIH.  Dr. Fugh-Berman is the former chair of, and currently writes a column for, the National Women's Health Network and she has appeared on 20/20, the Today Show and every major news network.  Dr. Fugh-Berman graduated from Georgetown University School of Medicine and completed a family medicine internship in the Residency Program in Social Medicine at Montefiore Hospital in the Bronx.For information regarding PharmedOut see: http://www.pharmedout.org/. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thehealthcarepolicypodcast.com

Charelle Lewis is a PMI certified IT Project Manager for GlaxoSmithKline (GSK) in Durham, North Carolina. A native of Houston, Texas, Charelle moved to Durham in August 2000 to attend Duke University, where she earned an undergraduate degree in Computer Science with a minor in Mathematics. After graduating from Duke, Charelle entered the IT Development Program at GSK. While in this program, she gained experience in several Professional IT roles including positions as Business Analyst, Process Improvement Analyst and Project Manager. She also earned her Six Sigma Certification. Charelle transitioned from the development program in 2008 and began working in the Strategy, Architecture and Information Group in North America Pharma IT (NAPIT). In this role she has served as the Program Administrator for the NAPIT Innovation Team, founded and chaired GSK’s Global IT Innovation Committee, and Co-Founded the Early Career Network for GSK’s Research Triangle Park campus. She currently serves as the Program Manager for the “eDetail” initiate which will deliver an iPad Application to the US Sales Force. During her 7 year tenure at GSK, Charelle has earned a Master of Engineering Management Degree from Duke University. In addition to her role at GSK, she has been an active member of the Durham Community serving on the Advisory Council for Trinity School, serving as an Ambassador for the Durham Young Professionals, and Directing/Engineering for the Media Team of World Overcomers Christian Church.

http://www.StockMarketFunding.com Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Wall St is hyping the suicidal results. We believe today's "pre market" manipulation in price action caused some large institutions to take a short position going into the move and the FDA Program Schedule Released at 8 AM today did not show any meaningful new data. Premarket high was $29.50 and now we're trading at $24.50 $5 dollars lower. The new breakthrough in Human Genome Sciences Benlysta drug approval for lupus patients. SMF will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues.BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010 – so it is possible that BENLYSTA could receive regulatory approval in the United States before the end of 2010.